




The  
Patent  
Office

Pat/E300/00248  
4  
INVESTOR IN PEOPLE

**PRIORITY  
DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

GB00/248

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ




I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



*P. Mahoney*

Signed

Dated 3 February 2000



**Request for grant of a patent**

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

29JAN99 E421459-1 000060  
P01/7700 0.00 - 99000000  
Cardiff Road  
Newport  
Gwent NP9 1RH

1. Your reference SMW/LP5745641

2. Patent application number  
(The Patent Office will fill in this part)**9901927.5**3. Full name, address and postcode of the or of each applicant (underline all surnames)JOHN INNES CENTRE  
NORWICH RESEARCH PARK  
COLNEY LANE  
NORWICH  
NORFOLK NR4 7UH  
UNITED KINGDOM

0554-6387001

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

GB

4. Title of the invention

METHODS AND MEANS FOR MODIFICATION OF PLANT CHARACTERISTICS

5. Name of your agent (if you have one)

MEWBURN ELLIS

"Address for service" in the United Kingdom to which all correspondence should be sent  
(including the postcode)YORK HOUSE  
23 KINGSWAY  
LONDON  
WC2B 6HP

Patents ADP number (if you know it)

109006 ✓

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number  
(if you know it)Date of filing  
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing  
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

YES

a) any applicant named in part 3 is not an inventor, or

b) there is an inventor who is not named as an applicant, or

c) any named applicant is a corporate body.

See note (d))

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form 0

Description 98

Claim(s) 0

Abstract 0

Drawing(s) 12

1084

112

10. If you are also filing any of the following, state

Priority documents 0

Translations of priority documents 0

Statement of inventorship and right to grant of a patent (Patents Form 7/77) 0

Request for preliminary examination and search (Patents Form 9/77) 0

Request for substantive examination (Patents Form 10/77) 0

Any other documents 0  
(Please specify)

11.

I/We request the grant of a patent on the basis of this application.

Signature

Seán M. Walton

Date

28 January 1999

12. Name and daytime telephone number of person to contact in the United Kingdom

SEÁN M. WALTON

0171 240 4405

### Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

### Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

METHODS AND MEANS FOR MODIFICATION  
OF PLANT CHARACTERISTICS

The present invention relates generally to modification of  
5 characteristics of plants, especially vernalization response,  
flowering time, leaf shape and/or shade avoidance response,  
and has arisen on the basis of cloning of the *VRN2* gene and  
mutant alleles of *Arabidopsis thaliana*, and identification of  
homologues in other species.

10

In different embodiments, the present invention provides for  
manipulation of flowering time and/or other characteristics of  
plants, e.g. by up or down regulating *VRN2* gene expression.  
The present invention also provides for modification of the  
15 extent of alteration of a relevant plant characteristic  
through the use of gene alleles, mutants and variants.

Plants must integrate a wide variety of environmental signals  
in order to maximize their reproductive success. Part of this  
20 integration must involve perception of the seasons, both to  
ensure the plant flowers during the correct season (for which  
it is adapted) and to synchronise its flowering with other  
members of its own species, to increase the chances of cross-  
fertilization. *Arabidopsis thaliana* serves as a model plant,  
25 for it exhibits responses to a wide variety of environmental  
stimuli that are observed in many species. Flowering in  
naturally occurring strains (ecotypes) of *Arabidopsis* can be  
promoted either by long days (increased photoperiod) or by  
vernalization, a long cold treatment that mimics the cold of

winter. While many aspects of the photoperiodic response are now understood, the vernalization pathway has received relatively less attention. The inventors have used a late flowering, vernalization responsive mutant of *Arabidopsis*, the *fca* mutant, as a background in which to isolate mutants that exhibit a reduced vernalization response, the VRN mutants.

Vernalization is the low temperature promotion of flowering. It can also be thought of as the cold aspect of the winter season, which also includes reduced daylight hours. Many species of plants that grow in temperate or cooler climes have an obligate requirement for vernalization in order to flower. Such plants typically germinate in autumn, and over winter as vegetative plants, and flower in milder conditions of spring. Vernalization thus acts as a cue, to allow plants to sense the seasons, and to time their flowering to maximise their chance of reproductive success.

Species for which flowering is important to crop production are numerous, essentially all crops which are grown from seed, with important examples being the cereals, rice and maize, probably the most agronomically important in warmer climatic zones, and wheat, barley, oats and rye in more temperate climates. Important seed products are oil seed rape, sugar beet, maize, sunflower, soybean and sorghum. Many crops which are harvested for their roots are, of course, grown annually from seed and the production of seed of any kind is very dependent upon the ability of the plant to flower, to be pollinated and to set seed. In horticulture, control of the

timing of flowering is important. Horticultural plants whose flowering may be controlled include lettuce, endive and vegetable brassicas including cabbage, broccoli and cauliflower, and carnations and geraniums.

5

*Arabidopsis thaliana* is a facultative long day plant, flowering early under long days and late under short days. Because it has a small, well-characterized genome, is relatively easily transformed and regenerated and has a rapid growing cycle, *Arabidopsis* is an ideal model plant in which to study flowering and its control.

10

In addition to cloning the VRN2 gene, the inventors have unexpectedly found indication that VRN2 is a transcription factor, which in itself opens several exciting avenues for application of the present invention. Without being bound by theory or in anyway limiting the scope of the present invention, VRN2 may be required for a normal vernalization response because it acts as a regulator of genes that ultimately lead to the transition from vegetative to reproductive growth. In such a model, cold, or a downstream molecule involved in cold perception, may regulate the activity or expression of the VRN2 protein, which in turn may regulate the expression of a large number of genes that ultimately lead to flowering. Furthermore, the shade avoidance phenotype exhibited by the *vrn2-1* mutant, as demonstrated experimentally below, provides indication that VRN2 also plays a role in regulating leaf shape, particularly in response to increased far-red light. Together, these two

20

25

processes affected by a deficiency or reduction of VRN2 activity provide for a number of approaches of agronomic interest.

5 First, forced expression of VRN2 (for example under the control of a strong and constitutive promoter, such as the Ca MV 35 S promoter) in a wild-type background may be used alter the vernalization requirement of a plant prior to flowering. As a large number of commercial cultivars of several species, including (diploid) wheat, barley, and sugar beet, have a requirement for vernalization to flower, modification of this requirement, by reducing the duration of vernalization required, or changing the optimum temperature, or abrogating the requirement altogether, is of agronomic usefulness. For instance, a winter crop that can be sown and left in the ground for a shorter period than usual (i.e. a reduced vernalization time) may benefit from reduced risk of damage associated with severe winter weather conditions, as the crops are exposed to winter conditions for a shorter time.

20

Second, down-regulation of VRN2 expression, for instance by means of an antisense VRN2 cDNA, may be used to recapitulate the reduction in shade avoidance phenotype observed in *vrn2-1* mutants. This may be used in situations where crowding of the crop is a problem. Based on experimental evidence provided herein on the phenotype of *vrn2-1* mutants, such plants are expected to exhibit less of a response to such conditions, and to produce leaves that are essentially normal i.e. as if they had not been grown in dense or crowded conditions.

25



Third, the individual isolated domains of the VRN2 protein may be used in their own right. DNA binding of the zinc finger of VRN2 may be used to direct or control gene expression in a precise manner. The VRN2 zinc finger may recognize specific DNA sequences that represent elements in the promoters of its normal target genes. By creating fusion proteins, comprising the DNA binding (zinc finger) domain of VRN2, and an activation or repression domain from a heterologous protein, the expression of VRN2 target genes may be controlled. This allows for a precise control of the expression of those genes that are normally targets of VRN2. Given that such genes, alone or in combination, ultimately control the transition to flowering (usually following vernalization), their directed expression in other conditions may also be used to elicit changes in flowering and/or one or more other plant characteristics. The response of a plant to far-red light may be controlled using VRN2 fusion proteins to control the expression of (far-red responsive) target genes. Furthermore, the use of the zinc finger domain of VRN2 in conventional SELEX or one-hybrid experiments may be used to reveal the target genes or DNA sequences normally bound by VRN2.

The acidic activation domain of VRN2 may be used to regulate the activity of a fusion protein, including a DNA-binding protein of known specificity, and the activation domain of VRN2. This allows for regulation of target genes of other DNA binding proteins involved in flowering, or of target genes in completely unrelated processes.

The inventors have cloned, characterised and manipulated the VRN2 gene of *Arabidopsis thaliana*, both *Columbia* and *Landsberg erecta* types, and identified alternatively spliced and mutant forms, also homologues in other species.

5

In the light of the inventors' experimental work, a first aspect of the present invention provides a nucleic acid isolate encoding a polypeptide including a VRN2 amino acid sequence shown herein (e.g. SEQ ID NO: 2; SEQ ID NO: 5), which  
10 may include a coding sequence shown herein (e.g. SEQ ID NO: 1; SEQ ID NO: 4).

Allelic forms and alternatively spliced forms of the gene have been identified. Such polypeptides and encoding nucleic acid  
15 (e.g. as in SEQ ID NO: 8, encoded by SEQ ID NO: 7) are each further provided as an aspect of the invention, as are polypeptides and nucleic acid including the mutations identified herein.

20 Nucleic acid according to the present invention may have the sequence of the VRN2 gene of *Arabidopsis thaliana* as indicated in SEQ ID NO: 1, SEQ ID NO: 3 (*Landsberg erecta* genomic sequence), SEQ ID NO: 4 or SEQ ID NO: 6 (*Columbia* genomic sequence), or be a mutant, variant, derivative or allele or a  
25 homologue of the sequence provided. Preferred mutants, variants, derivatives and alleles are those which encode a protein which retains a functional characteristic of the protein encoded by the wild-type gene, especially the ability to alter vernalization response, flowering time, leaf shape

and/or shade avoidance response.

A mutant, variant, derivative, allele or homologue in accordance with the present invention may have the ability to affect a physical characteristic of a plant, especially vernalization response, flowering time, leaf shape and/or shade avoidance response, as discussed.

Polynucleotides which are not 100% identical to the sequences shown herein but fall within the scope of the invention can be obtained in a number of ways.

Other *VRN2* variants (for example allelic forms) of the gene described herein may be obtained for example by probing cDNA or genomic DNA libraries made from *Arabidopsis thaliana* plants or cells.

In addition, other plant, monocot or dicot, homologues of the gene may be obtained. Such sequences may be obtained by making or obtaining cDNA libraries made from dividing cells or tissues or genomic DNA libraries from other plant species, and probing such libraries with probes comprising all or part of a nucleic acid of the invention under conditions of medium to high stringency (for example for hybridization on a solid support (filter) overnight incubation at 42°C in a solution containing 50% formamide, 5xSSC (750 mM NaCl, 75 mM sodium citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt's solution, 10% dextran sulphate and 20 µg/ml salmon sperm DNA, followed by washing in 0.03M sodium chloride and 0.03M sodium

citrate (i.e. 0.2x SSC) at from about 50°C to about 60°C).

Thus the present invention provides an isolated nucleic acid which hybridizes to the nucleotide sequence shown in a figure  
5 herein under the abovementioned hybridization and washing conditions. Such a nucleic acid is suitable for use as a probe for detecting the *VRN2* gene, for example in Southern blots.

10 Suitable probe and primer sequences are disclosed herein.

Alternatively, polynucleotides of the invention may be obtained by site directed mutagenesis of the sequences of shown in the figures or allelic variants thereof. This may be  
15 useful where for example silent codon changes are required to sequences to optimise codon preferences for a particular host cell in which the polynucleotide sequences are being expressed. Other sequence changes may be desired in order to introduce restriction enzyme recognition sites, or to alter  
20 the property or function of the polypeptides encoded by the polynucleotides. Further changes may be desirable to represent particular coding changes which are required to provide, for example, conservative substitutions.

25 In the context of cloning, it may be necessary for one or more gene fragments to be ligated to generate a full-length coding sequence. Also, where a full-length encoding nucleic acid molecule has not been obtained, a smaller molecule representing part of the full molecule, may be used to obtain

full-length clones. Inserts may be prepared from partial cDNA clones and used to screen cDNA libraries. The full-length clones isolated may be subcloned into expression vectors and activity assayed by transfection into suitable host cells, e.g. with a reporter plasmid.

The present invention also extends to nucleic acid comprising transcriptional control sequences for the VRN2 gene. Such control sequences will be found 5' to the open reading frame of the gene and are obtainable by probing a genomic DNA library with a nucleic acid of the invention, selecting a clone which hybridizes under conditions of medium to high stringency, and sequencing the clone 5' to the open reading frame of the gene. Where only a small amount of sequence is present in the 5' region, this sequence may be used to reprobe the library to genome walk further upstream. Analysis of the upstream region will reveal control regions for gene expression including control regions common to many genes (i.e. TATA and CAAT boxes) and other control regions, usually located from 1 to 10,000, such as 1 to 1000 or 50 to 500 nucleotides upstream of the start of transcription.

To confirm that such regions are the control regions of the gene, they may be linked to a reported gene (such as  $\beta$ -galactosidase) and tested in any suitable *in vitro* or *in vivo* system. For example the construct of the control region (e.g. comprising 50 to 500 nucleotides upstream of the start of transcription) and the reporter gene may be used to produce a transgenic plant and the pattern of expression, both spatially

and developmentally, may be compared with that of the VRN2 gene. Where substantially similar patterns of expression are found, this shows that the construct comprises substantially all of the control region of the wild type gene.

5

SEQ ID NO: 3 and SEQ ID NO: 6 show the nucleotide sequence of the VRN2 genomic region including promoter, respectively for *Landsberg erecta* and *Columbia* ecotypes of *Arabidopsis thaliana*, also 3' regulatory elements.

10

The control region may be mutated to identify specific subregions responsible for transcriptional control. This may be achieved by a number of techniques well known in the art as such, including DNase protection footprint assays, in which  
15 the control region is brought into contact with an extract from a cell in which the VRN2 gene is actively expressed, and the regions of the control region which bind factors in that extract is determined.

20 Isolated nucleic acid comprising such control regions obtainable by such a method form a further aspect of the present invention.

The present invention further extends to genomic DNA exon  
25 sequences found between the introns encoding a VRN2 gene in plant. Such exon sequences may be obtained in a manner analogous to that described above for the transcriptional control sequences, with the appropriate genome walking being conducted between the intron sequences. The locations of the

exons may be determined by comparing genomic and cDNA sequences of the gene, observing where the sequences line up and diverge, and looking for consensus splice sequences which define intron/exon boundaries.

5

As noted above, changes to a sequence, to produce a mutant, variant or derivative, may be by one or more of addition, insertion, deletion or substitution of one or more nucleotides in the nucleic acid, leading to the addition, insertion, deletion or substitution of one or more amino acids in the encoded polypeptide. Of course, changes to the nucleic acid which make no difference to the encoded amino acid sequence ("degeneratively equivalent") are included.

15 Preferred nucleic acid sequences according to the present invention are shown herein, for instance see SEQ ID NO: 1 and SEQ ID NO: 4, of which the respective predicted encoded amino acid sequences of polypeptides according to the present invention are shown in SEQ ID NO: 2 and SEQ ID NO: 5.

20

A mutant, allele, variant or derivative amino acid sequence in accordance with the present invention may include within a sequence shown herein a single amino acid change with respect to the sequence shown with the relevant SEQ ID NO: or in the relevant figure, or 2, 3, 4, 5, 6, 7, 8, or 9 changes, about 10, 15, 20, 30, 40 or 50 changes, or greater than about 50, 60, 70, 80 or 90 changes. In addition to one or more changes within the amino acid sequence shown in the relevant figure, a mutant, allele, variant or derivative amino acid sequence may

include additional amino acids at the C-terminus and/or N-terminus.

A sequence related to a sequence specifically disclosed herein  
5 shares homology with that sequence. Homology may be at the nucleotide sequence and/or amino acid sequence level.

Preferably, the nucleic acid and/or amino acid sequence shares homology with the coding sequence or the sequence encoded by a nucleotide sequence shown herein, for instance SEQ ID NO: 2 or  
10 SEQ ID NO: 5, preferably at least about 50%, or 60%, or 70%, or 80% homology, most preferably at least about 90%, 95%, 96%, 97%, 98% or 99% homology.

As is well-understood, homology at the amino acid level is  
15 generally in terms of amino acid similarity or identity.

Similarity allows for "conservative variation", i.e. substitution of one hydrophobic residue such as isoleucine, valine, leucine or methionine for another, or the substitution of one polar residue for another, such as arginine for lysine,  
20 glutamic for aspartic acid, or glutamine for asparagine.

Similarity may be as defined and determined by the TBLASTN program, of Altschul et al. (1990) *J. Mol. Biol.* 215: 403-10, which is in standard use in the art, or, and this may be preferred, either of the standard programs BestFit and GAP,  
25 which are part of the Wisconsin Package, Version 8, September 1994, (Genetics Computer Group, 575 Science Drive, Madison, Wisconsin, USA, Wisconsin 53711). BestFit makes an optimal alignment of the best segment of similarity between two sequences. Optimal alignments are found by inserting gaps to



maximize the number of matches using the local homology algorithm of Smith and Waterman (Advances in Applied Mathematics (1981) 2, pp. 482-489). GAP uses the Needleman and Wunsch algorithm to align two complete sequences that

5 maximizes the number of matches and minimizes the number of gaps. Generally, the default parameters are used, with a gap creation penalty = 12 and gap extension penalty = 4.

Homology is generally over the full-length of the relevant  
10 sequence shown herein, that is unless stated otherwise, or it may be over a contiguous sequence of about or greater than about 20, 25, 30, 33, 40, 50, 67, 133, 167, 200, 233, 267, 300, 333, 400, 450, 500, 550, 600 or more amino acids or codons, compared with the relevant amino acid sequence or  
15 nucleotide sequence as the case may be.

Nucleic acid according to the present invention may consist essentially of or consist of the relevant coding sequence.

Nucleic acid according to the present invention may include a  
20 promoter or other regulatory sequence as discussed further elsewhere herein, and such regulatory sequence may be heterologous to the coding sequence, that is to say not naturally operably linked therewith. Nucleic acid according to the present invention may be cDNA or lacking one or more  
25 introns which occur naturally, or may be in any non-naturally occurring form. A coding sequence in accordance with the present invention may be included with a larger nucleic acid molecule of less than about 10,000 nucleotides, less than about 5,000 nucleotides or less than about 2,000 nucleotides.

Also provided by an aspect of the present invention is nucleic acid including or consisting essentially of a sequence of nucleotides complementary to a nucleotide sequence hybridisable with any encoding sequence provided herein.

- 5 Another way of looking at this would be for nucleic acid according to this aspect to be hybridisable with a nucleotide sequence complementary to any encoding sequence provided herein. Of course, DNA is generally double-stranded and blotting techniques such as Southern hybridisation are often
- 10 performed following separation of the strands without a distinction being drawn between which of the strands is hybridising. Preferably the hybridisable nucleic acid or its complement encode a product able to influence a physical characteristic of a plant, particularly vernalization
- 15 response, flowering time, leaf shape and/or shade avoidance response, e.g. in *Arabidopsis thaliana*. Preferred conditions for hybridisation are familiar to those skilled in the art, but are generally stringent enough for there to be positive hybridisation between the sequences of interest to the
- 20 exclusion of other sequences.

The nucleic acid, which may contain for example DNA encoding a polypeptide including the amino acid sequence of VRN2 or other polypeptide disclosed herein, as genomic or cDNA, may be in

25 the form of a recombinant and preferably replicable vector, for example a plasmid, cosmid, phage or *Agrobacterium* binary vector. The nucleic acid may be under the control of an appropriate promoter or other regulatory elements for expression in a host cell such as a microbial, e.g. bacterial,

or plant cell. In the case of genomic DNA, this may contain its own promoter or other regulatory elements and in the case of cDNA this may be under the control of an appropriate promoter or other regulatory elements for expression in the host cell.

A vector including nucleic acid according to the present invention need not include a promoter or other regulatory sequence, particularly if the vector is to be used to introduce the nucleic acid into cells for recombination into the genome.

Those skilled in the art are well able to construct vectors and design protocols for recombinant gene expression. Suitable vectors can be chosen or constructed, containing appropriate regulatory sequences, including promoter sequences, terminator fragments, polyadenylation sequences, enhancer sequences, marker genes and other sequences as appropriate. For further details see, for example, *Molecular Cloning: a Laboratory Manual*: 2nd edition, Sambrook et al, 1989, Cold Spring Harbor Laboratory Press. Many known techniques and protocols for manipulation of nucleic acid, for example in preparation of nucleic acid constructs, mutagenesis, sequencing, introduction of DNA into cells and gene expression, and analysis of proteins, are described in detail in *Current Protocols in Molecular Biology*, Second Edition, Ausubel et al. eds., John Wiley & Sons, 1992. The disclosures of Sambrook et al. and Ausubel et al. are incorporated herein by reference. Specific procedures and

vectors previously used with wide success upon plants are described by Bevan (Nucl. Acids Res. 12, 8711-8721 (1984)) and Guerineau and Mullineaux (1993) (Plant transformation and expression vectors. In: Plant Molecular Biology Labfax (Croy  
5 RRD ed) Oxford, BIOS Scientific Publishers, pp 121-148).

Selectable genetic markers may be used consisting of chimaeric genes that confer selectable phenotypes such as resistance to antibiotics such as kanamycin, hygromycin, phosphinotricin,  
10 chlorsulfuron, methotrexate, gentamycin, spectinomycin, imidazolinones and glyphosate.

Nucleic acid molecules and vectors according to the present invention may be provided isolated and/or purified from their  
15 natural environment, in substantially pure or homogeneous form, or free or substantially free of nucleic acid or genes of the species of interest or origin other than the sequence encoding a polypeptide with the required function. Nucleic acid according to the present invention may include cDNA,  
20 RNA, genomic DNA and may be wholly or partially synthetic. The term "isolate" encompasses all these possibilities. Where a DNA sequence is specified, e.g. with reference to a figure, unless context requires otherwise the RNA equivalent, with U substituted for T where it occurs, is encompassed.

25

When introducing a chosen gene construct into a cell, certain considerations must be taken into account, well known to those skilled in the art. The nucleic acid to be inserted should be assembled within a construct which contains effective

regulatory elements which will drive transcription. There must be available a method of transporting the construct into the cell. Once the construct is within the cell membrane, integration into the endogenous chromosomal material either will or will not occur. Finally, as far as plants are concerned the target cell type must be such that cells can be regenerated into whole plants.

Plants transformed with the DNA segment containing the sequence may be produced by standard techniques which are already known for the genetic manipulation of plants. DNA can be transformed into plant cells using any suitable technology, such as a disarmed Ti-plasmid vector carried by *Agrobacterium* exploiting its natural gene transfer ability (EP-A-270355, EP-A-0116718, NAR 12(22) 8711 - 87215 1984), particle or microprojectile bombardment (US 5100792, EP-A-444882, EP-A-434616) microinjection (WO 92/09696, WO 94/00583, EP 331083, EP 175966, Green et al. (1987) *Plant Tissue and Cell Culture*, Academic Press), electroporation (EP 290395, WO 8706614) other forms of direct DNA uptake (DE 4005152, WO 9012096, US 4684611), liposome mediated DNA uptake (e.g. Freeman et al. *Plant Cell Physiol.* 29: 1353 (1984)), or the vortexing method (e.g. Kindle, *PNAS U.S.A.* 87: 1228 (1990d) Physical methods for the transformation of plant cells are reviewed in Oard, 1991, *Biotech. Adv.* 9: 1-11.

*Agrobacterium* transformation is widely used by those skilled in the art to transform dicotyledonous species. There are various approaches used for the routine production of stable,

fertile transgenic plants in almost all economically relevant monocot plants (Toriyama, et al. (1988) *Bio/Technology* 6, 1072-1074; Zhang, et al. (1988) *Plant Cell Rep.* 7, 379-384; Zhang, et al. (1988) *Theor Appl Genet* 76, 835-840; Shimamoto, et al. (1989) *Nature* 338, 274-276; Datta, et al. (1990) *Bio/Technology* 8, 736-740; Christou, et al. (1991) *Bio/Technology* 9, 957-962; Peng, et al. (1991) International Rice Research Institute, Manila, Philippines 563-574; Cao, et al. (1992) *Plant Cell Rep.* 11, 585-591; Li, et al. (1993) *Plant Cell Rep.* 12, 250-255; Rathore, et al. (1993) *Plant Molecular Biology* 21, 871-884; Fromm, et al. (1990) *Bio/Technology* 8, 833-839; Gordon-Kamm, et al. (1990) *Plant Cell* 2, 603-618; D'Halluin, et al. (1992) *Plant Cell* 4, 1495-1505; Walters, et al. (1992) *Plant Molecular Biology* 18, 189-200; Koziel, et al. (1993) *Biotechnology* 11, 194-200; Vasil, I. K. (1994) *Plant Molecular Biology* 25, 925-937; Weeks, et al. (1993) *Plant Physiology* 102, 1077-1084; Somers, et al. (1992) *Bio/Technology* 10, 1589-1594; WO92/14828). In particular, *Agrobacterium* mediated transformation is now emerging also as an highly efficient alternative transformation method in monocots (Hiei et al. (1994) *The Plant Journal* 6, 271-282).

The generation of fertile transgenic plants has been achieved in the cereals rice, maize, wheat, oat, and barley (reviewed in Shimamoto, K. (1994) *Current Opinion in Biotechnology* 5, 158-162.; Vasil, et al. (1992) *Bio/Technology* 10, 667-674; Vain et al., 1995, *Biotechnology Advances* 13 (4): 653-671; Vasil, 1996, *Nature Biotechnology* 14 page 702).

Microprojectile bombardment, electroporation and direct DNA uptake are preferred where *Agrobacterium* is inefficient or ineffective. Alternatively, a combination of different techniques may be employed to enhance the efficiency of the transformation process, eg bombardment with *Agrobacterium* coated microparticles (EP-A-486234) or microprojectile bombardment to induce wounding followed by co-cultivation with *Agrobacterium* (EP-A-486233).

10 Following transformation, a plant may be regenerated, e.g. from single cells, callus tissue or leaf discs, as is standard in the art. Almost any plant can be entirely regenerated from cells, tissues and organs of the plant. Available techniques are reviewed in Vasil et al., *Cell Culture and Somatic Cell*  
15 *Genetics of Plants, Vol I, II and III, Laboratory Procedures and Their Applications*, Academic Press, 1984, and Weissbach and Weissbach, *Methods for Plant Molecular Biology*, Academic Press, 1989.

20 The particular choice of a transformation technology will be determined by its efficiency to transform certain plant species as well as the experience and preference of the person practising the invention with a particular methodology of choice. It will be apparent to the skilled person that the  
25 particular choice of a transformation system to introduce nucleic acid into plant cells is not essential to or a limitation of the invention, nor is the choice of technique for plant regeneration.

A *VRN2* gene and modified versions thereof (alleles, mutants, variants and derivatives thereof), and other nucleic acid provided herein, including species homologues, may be used to modify vernalization response, flowering time, leaf shape and/or shade avoidance response in a transgenic plant. Nucleic acid such as a vector as described herein may be used for the production of a transgenic plant. Such a plant may possess an altered phenotype, particular in terms of vernalization response, flowering time, leaf shape and/or shade avoidance response compared with wild-type (that is to say a plant that is wild-type for *VRN2* or the relevant homologue thereof).

The invention further encompasses a host cell transformed with nucleic acid or a vector according to the present invention, especially a plant or a microbial cell. Thus, a host cell, such as a plant cell, including heterologous nucleic acid according to the present invention is provided. Within the cell, the nucleic acid may be incorporated within the chromosome. There may be more than one heterologous nucleotide sequence per haploid genome.

Also according to the invention there is provided a plant cell having incorporated into its genome nucleic acid, particularly heterologous nucleic acid, as provided by the present invention, under operative control of a regulatory sequence for control of expression. The coding sequence may be operably linked to one or more regulatory sequences which may be heterologous or foreign to the gene, such as not naturally



associated with the gene for its expression. The nucleic acid according to the invention may be placed under the control of an externally inducible gene promoter to place expression under the control of the user.

5

A suitable inducible promoter is the GST-II-27 gene promoter which has been shown to be induced by certain chemical compounds which can be applied to growing plants. The promoter is functional in both monocotyledons and

10 dicotyledons. It can therefore be used to control gene expression in a variety of genetically modified plants, including field crops such as canola, sunflower, tobacco, sugarbeet, cotton; cereals such as wheat, barley, rice, maize, sorghum; fruit such as tomatoes, mangoes, peaches, apples,  
15 pears, strawberries, bananas, and melons; and vegetables such as carrot, lettuce, cabbage and onion. The GST-II-27 promoter is also suitable for use in a variety of tissues, including roots, leaves, stems and reproductive tissues.

20 A further aspect of the present invention provides a method of making such a plant cell involving introduction of nucleic acid or a suitable vector including the sequence of nucleotides into a plant cell and causing or allowing recombination between the vector and the plant cell genome to  
25 introduce the sequence of nucleotides into the genome. The invention extends to plant cells containing nucleic acid according to the invention as a result of introduction of the nucleic acid into an ancestor cell.

The term "heterologous" may be used to indicate that the gene/sequence of nucleotides in question have been introduced into said cells of the plant or an ancestor thereof, using genetic engineering, ie by human intervention. A transgenic  
5 plant cell, i.e. transgenic for the nucleic acid in question, may be provided. The transgene may be on an extra-genomic vector or incorporated, preferably stably, into the genome. A heterologous gene may replace an endogenous equivalent gene, ie one which normally performs the same or a similar function,  
10 or the inserted sequence may be additional to the endogenous gene or other sequence. An advantage of introduction of a heterologous gene is the ability to place expression of a sequence under the control of a promoter of choice, in order to be able to influence expression according to preference.  
15 Furthermore, mutants, variants and derivatives of the wild-type gene, e.g. with higher or lower activity than wild-type, may be used in place of the endogenous gene. Nucleic acid heterologous, or exogenous or foreign, to a plant cell may be non-naturally occurring in cells of that type, variety or  
20 species. Thus, nucleic acid may include a coding sequence of or derived from a particular type of plant cell or species or variety of plant, placed within the context of a plant cell of a different type or species or variety of plant. A further possibility is for a nucleic acid sequence to be placed within  
25 a cell in which it or a homologue is found naturally, but wherein the nucleic acid sequence is linked and/or adjacent to nucleic acid which does not occur naturally within the cell, or cells of that type or species or variety of plant, such as operably linked to one or more regulatory sequences, such as a

promoter sequence, for control of expression. A sequence within a plant or other host cell may be identifiably heterologous, exogenous or foreign.

- 5 Plants which include a plant cell according to the invention are also provided, along with any part or propagule thereof, seed, selfed or hybrid progeny and descendants. A plant according to the present invention may be one which does not breed true in one or more properties. Plant varieties may be
- 10 excluded, particularly registrable plant varieties according to Plant Breeders' Rights. It is noted that a plant need not be considered a "plant variety" simply because it contains stably within its genome a transgene, introduced into a cell of the plant or an ancestor thereof.

15

- In addition to a plant, the present invention provides any clone of such a plant, seed, selfed or hybrid progeny and descendants, and any part of any of these, such as cuttings, seed. The invention provides any plant propagule, that is any
- 20 part which may be used in reproduction or propagation, sexual or asexual, including cuttings, seed and so on. Also encompassed by the invention is a plant which is a sexually or asexually propagated off-spring, clone or descendant of such a plant, or any part or propagule of said plant, off-spring,
- 25 clone or descendant.

The invention further provides a method of influencing or affecting a physical characteristic of a plant, particularly vernalization response, flowering time, leaf shape and/or

shade avoidance response, including causing or allowing expression of a heterologous nucleic acid sequence as discussed within cells of the plant.

- 5 The invention further provides a method of including expression from nucleic acid encoding a VRN2 polypeptide, or a mutant, variant, allele or derivative of the sequence, or a homologue, according to the disclosure herein, within cells of a plant (thereby producing the encoded polypeptide), following  
10 an earlier step of introduction of the nucleic acid into a cell of the plant or an ancestor thereof. Such a method may influence or affect a characteristic of the plant, such as vernalization response, flowering time, leaf shape and/or shade avoidance response. This may be used in combination  
15 with any other gene, such as transgenes involved in flowering (e.g. FCA) or other phenotypic trait or desirable property.

The present invention also encompasses the expression product of any of the nucleic acid sequences disclosed and methods of  
20 making the expression product by expression from encoding nucleic acid therefore under suitable conditions, which may be in suitable host cells. Following expression, the product may be isolated from the expression system and may be used as desired, for instance in formulation of a composition  
25 including at least one additional component.

The present invention also provides for the production and use of fragments of the full-length polypeptides disclosed herein, especially active portions thereof. An "active portion" of a

polypeptide means a peptide which is less than said full length polypeptide, but which retains an essential biological activity. In particular, the active portion retains the ability to alter vernalization response, flowering time, leaf shape and/or shade avoidance response in a plant, such as *Arabidopsis thaliana*.

A "fragment" of a polypeptide means a stretch of amino acid residues of at least about five to seven contiguous amino acids, often at least about seven to nine contiguous amino acids, typically at least about nine to 13 contiguous amino acids and, most preferably, at least about 20 to 30 or more contiguous amino acids. Fragments of the polypeptides may include one or more epitopes useful for raising antibodies to a portion of any of the amino acid sequences disclosed herein. Preferred epitopes are those to which antibodies are able to bind specifically, which may be taken to be binding a polypeptide or fragment thereof of the invention with an affinity which is at least about 1000x that of other polypeptides.

Among preferred VRN2 fragments according to the present invention are the zinc finger domain, DNA binding domain and other domains disclosed herein.

25

Purified protein according to the present invention, or a fragment, mutant, derivative or variant thereof, e.g. produced recombinantly by expression from encoding nucleic acid therefor, may be used to raise antibodies employing techniques

which are standard in the art. Antibodies and polypeptides comprising antigen-binding fragments of antibodies may be used in identifying homologues from other species as discussed further below, also in identifying complexes containing VRN2  
5 protein.

Methods of producing antibodies include immunising a mammal (e.g. human, mouse, rat, rabbit, horse, goat, sheep or monkey) with the protein or a fragment thereof. Antibodies may be  
10 obtained from immunised animals using any of a variety of techniques known in the art, and might be screened, preferably using binding of antibody to antigen of interest. For instance, Western blotting techniques or immunoprecipitation may be used (Armitage et al, 1992, Nature 357: 80-82).  
15 Antibodies may be polyclonal or monoclonal.

As an alternative or supplement to immunising a mammal, antibodies with appropriate binding specificity may be obtained from a recombinantly produced library of expressed  
20 immunoglobulin variable domains, e.g. using lambda bacteriophage or filamentous bacteriophage which display functional immunoglobulin binding domains on their surfaces; for instance see WO92/01047.

25 Antibodies raised to a polypeptide or peptide can be used in the identification and/or isolation of homologous polypeptides, and then the encoding genes. Thus, the present invention provides a method of identifying or isolating a polypeptide with the desired function (in accordance with

embodiments disclosed herein), comprising screening candidate polypeptides with a polypeptide comprising the antigen-binding domain of an antibody (for example whole antibody or a suitable fragment thereof, e.g. scFv, Fab) which is able to bind a polypeptide or fragment, variant or derivative thereof according to the present invention or preferably has binding specificity for such a polypeptide. Specific binding members such as antibodies and polypeptides comprising antigen binding domains of antibodies that bind and are preferably specific for a polypeptide or mutant, variant or derivative thereof according to the invention represent further aspects of the present invention, particularly in isolated and/or purified form, as do their use and methods which employ them.

Candidate polypeptides for screening may for instance be the products of an expression library created using nucleic acid derived from an plant of interest, or may be the product of a purification process from a natural source. A polypeptide found to bind the antibody may be isolated and then may be subject to amino acid sequencing. Any suitable technique may be used to sequence the polypeptide either wholly or partially (for instance a fragment of the polypeptide may be sequenced). Amino acid sequence information may be used in obtaining nucleic acid encoding the polypeptide, for instance by designing one or more oligonucleotides (e.g. a degenerate pool of oligonucleotides) for use as probes or primers in hybridization to candidate nucleic acid, or by searching computer sequence databases, as discussed further below.

A further aspect of the present invention provides a method of identifying and cloning *VRN2* homologues from plant species other than *Arabidopsis thaliana* which method employs a nucleotide sequence derived from that shown herein. As  
5 discussed above, sequences derived from these may themselves be used in identifying and in cloning other sequences. The nucleotide sequence information provided herein, or any part thereof, may be used in a data-base search to find homologous sequences, expression products of which can be tested for  
10 ability to influence a plant characteristic. These may have ability to alter vernalization response, flowering time, leaf shape and/or shade avoidance response in a plant. Alternatively, nucleic acid libraries may be screened using techniques well known to those skilled in the art and  
15 homologous sequences thereby identified then tested.

The present invention also extends to nucleic acid encoding a *VRN2* homologue obtained using a nucleotide sequence derived from any of those shown herein.

20

In certain embodiments, nucleic acid according to the present invention encodes a polypeptide which has homology with all or part of *VRN2* amino acid sequence shown herein, in the terms discussed already above (e.g. for length), which homology is  
25 greater over the length of the relevant part (i.e. fragment) than the homology shared between a respective part of the *VRN2* amino acid sequence of *Arabidopsis thaliana*, and the other sequences shown in Figure 8a or Figure 8b, and may be greater than about 5% greater, more preferably greater than about 10%



greater, more preferably greater than about 20% greater, and more preferably greater than about 30% greater. Thus, to exemplify with reference to one embodiment, nucleic acid encoding an amino acid mutant, variant or derivative of the

5 amino acid sequence shown in SEQ ID NO: 2 may be provided wherein the encoded amino acid sequence includes a contiguous sequence of about 100 amino acids which has greater homology with a contiguous sequence of 100 amino acids within the amino acid sequence of SEQ ID NO: 2 than any contiguous sequence of  
10 100 amino acids within another sequence shown in Figure 8a or 8b, preferably greater than about 5% greater homology, and so on.

Similarly, nucleic acid according to certain embodiments of  
15 the present invention may have homology with all or part of a nucleotide sequence shown herein, in the terms discussed already above (e.g. for length), which homology is greater over the length of the relevant part (i.e. fragment) than the  
homology shared with a respective part of the natural coding  
20 nucleotide sequence for the other amino acid sequences shown in Figure 8a or 8b and referenced herein, and may be greater than about 5% greater, more preferably greater than about 10% greater, more preferably greater than about 20% greater, and more preferably greater than about 30% greater.

25

The provision of sequence information for the VRN2 gene of *Arabidopsis thaliana* enables the obtention of homologous sequences from other plant species. In particular, homologues may be easily isolated from related, commercially

important species that have a vernalization requirement, or show some response to vernalization. These would include all members of the Brassicaceae, and other dicots including tobacco, sugarbeet, peas and celery. Monocots included in  
5 this category are the cereals rice, wheat and barley.

Thus, included within the scope of the present invention are nucleic acid molecules which encode amino acid sequences which are homologues of *VRN2* of *Arabidopsis thaliana*. Homology may  
10 be at the nucleotide sequence and/or amino acid sequence level, as has already been discussed above. A homologue from a species other than *Arabidopsis thaliana* encodes a product which causes a phenotype similar to that caused by the *VRN2* gene, generally including ability to alter vernalization  
15 response, flowering time, leaf shape and/or shade avoidance response in a plant, such as in *Arabidopsis thaliana*. In addition, mutants, derivatives or alleles of these genes may have altered, e.g. increased or decreased, activity or ability compared with wild-type.

20

*VRN2* gene homologues may also be identified from economically important monocotyledonous crop plants including the cereals rice, wheat and barley. Although genes encoding the same protein in monocotyledonous and dicotyledonous plants show  
25 relatively little homology at the nucleotide level, amino acid sequences are conserved. Therefore it is possible to use public sequence databases to identify *Arabidopsis*, rice or maize cDNA clone sequences that were obtained in random sequencing programmes and share homology to the gene of

interest, as has been done for other genes isolated from  
Arabidopsis (e.g CO; WO 96/14414). Of course, mutants,  
derivatives and alleles of these sequences are included within  
the scope of the present invention in the same terms as  
5 discussed above for the *Arabidopsis thaliana* VRN2 gene.

According to a further aspect, the present invention provides  
a method of identifying or a method of cloning a VRN2  
homologue, e.g. from a species other than *Arabidopsis thaliana*  
10 the method employing a nucleotide sequence derived from any of  
those shown herein. For instance, such a method may employ an  
oligonucleotide or oligonucleotides which comprises or  
consists of a sequence or sequences conserved between or  
encoding a sequence or sequences conserved between the  
15 sequences shown in Figure 8a or 8b, or a sequence or sequences  
conserved between the sequences of SEQ ID NO: 2 and SEQ ID NO:  
5, or encoding sequences SEQ ID NO: 1 and SEQ ID NO: 4, to  
search for homologues. Thus, a method of obtaining nucleic  
acid is provided, comprising hybridisation of an  
20 oligonucleotide or a nucleic acid molecule comprising such an  
oligonucleotide to target/candidate nucleic acid. Target or  
candidate nucleic acid may, for example, comprise a genomic or  
cDNA library obtainable from an organism known to contain or  
suspected of containing such nucleic acid, either  
25 monocotyledonous or dicotyledonous. Successful hybridisation  
may be identified and target/candidate nucleic acid isolated  
for further investigation and/or use.

Hybridisation may involve probing nucleic acid and identifying

positive hybridisation under suitably stringent conditions (in accordance with known techniques) and/or use of oligonucleotides as primers in a method of nucleic acid amplification, such as PCR. For probing, preferred conditions are those which are stringent enough for there to be a simple pattern with a small number of hybridisations identified as positive which can be investigated further. It is well known in the art to increase stringency of hybridisation gradually until only a few positive clones remain.

10

For instance, screening may initially be carried out under conditions, which comprise a temperature of about 37°C or more, a formamide concentration of less than about 50%, and a moderate to low salt (e.g. Standard Saline Citrate ('SSC') = 0.15 M sodium chloride; 0.15 M sodium citrate; pH 7) concentration.

15

Alternatively, a temperature of about 50°C or more and a high salt (e.g. 'SSPE' = 0.180 M sodium chloride; 9 mM disodium hydrogen phosphate; 9 mM sodium dihydrogen phosphate; 1 mM sodium EDTA; pH 7.4). Preferably the screening is carried out at about 37°C, a formamide concentration of about 20%, and a salt concentration of about 5 X SSC, or a temperature of about 50°C and a salt concentration of about 2 X SSPE. These conditions will allow the identification of sequences which have a substantial degree of homology (similarity, identity) with the probe sequence, without requiring the perfect homology for the identification of a stable hybrid.

25

Suitable conditions include, e.g. for detection of sequences that are about 80-90% identical, hybridization overnight at 42°C in 0.25M Na<sub>2</sub>HPO<sub>4</sub>, pH 7.2, 6.5% SDS, 10% dextran sulfate and a final wash at 55°C in 0.1X SSC, 0.1% SDS. For detection  
5 of sequences that are greater than about 90% identical, suitable conditions include hybridization overnight at 65°C in 0.25M Na<sub>2</sub>HPO<sub>4</sub>, pH 7.2, 6.5% SDS, 10% dextran sulfate and a final wash at 60°C in 0.1X SSC, 0.1% SDS.

10 An alternative is a solution of 5x SSPE (final 0.9 M NaCl, 0.05M sodium phosphate, 0.005M ethylenediaminetetraacetic acid (EDTA) pH 7.7), 5X Denhardt's solution, 0.5% SDS (sodium dodecyl sulphate), at 65°C overnight, (for high stringency, highly similar sequences) or 50°C (for low stringency, less  
15 similar sequences). Washes in 0.2x SSC/0.1% SDS at 65°C for high stringency, alternatively at 50-60°C in 1x SSC/0.1%SDS for low stringency.

The present invention extends to nucleic acid selectively  
20 hybridisable under high stringency with nucleic acid identified herein.

As an alternative to probing, though still employing nucleic acid hybridisation, oligonucleotides designed to amplify DNA  
25 sequences may be used in PCR reactions or other methods involving amplification of nucleic acid, using routine procedures. See for instance "PCR protocols; A Guide to Methods and Applications", Eds. Innis et al, 1990, Academic Press, New York.

Preferred amino acid sequences suitable for use in the design of probes or PCR primers for some purposes are sequences conserved (completely, substantially or partly) between the VRN2 sequence and at least one other of the sequences shown in  
5 Figure 8a or 8b.

Preferred primers for amplification of conserved regions of VRN2 for use as probes to obtain genomic or cDNA clones may include the following:

10

Primers VRN2-AI and VRN2-AJ which, in RT-PCR, amplify a 1583 bp fragment that contains the complete VRN2 open reading frame, and portions of both the 5' and 3' untranslated sequences;

15

Primers VRN2-AP and VRN2-AJ which, in RT-PCR, amplify a 781 bp fragment that includes the conserved acidic region;

Primers VRN2-AO and VRN2-AS which, in RT-PCR, amplify a 493 bp  
20 fragment that includes the zinc-finger motif, and the second nuclear localization signal (NLS); and

Primers VRN2-AI and VRN2-AJ from genomic DNA, which amplify a 3605 bp product that includes most of the VRN2 gene, except  
25 the promoter and 3' regions (i.e. encompasses the same regions as the VRN2-AI/AJ pair above, but with the introns, useful for hybridisation to genomic DNA, less so for cDNA).

On the basis of amino acid sequence information

oligonucleotide probes or primers may be designed, taking into account the degeneracy of the genetic code, and, where appropriate, codon usage of the organism from the candidate nucleic acid is derived.

5

Preferably an oligonucleotide in accordance with certain embodiments of the invention, e.g. for use in nucleic acid amplification, is up to about 50 nucleotides, or about 40 nucleotides or about 30 or fewer nucleotides in length (e.g. 18, 21 or 24).

10

Assessment of whether or not such a PCR product corresponds to a homologue gene may be conducted in various ways. A PCR band from such a reaction might contain a complex mix of products.

15 Individual products may be cloned and each one individually screened. It may be analysed by transformation to assess function on introduction into a plant of interest.

As noted, nucleic acid according to the present invention is obtainable using oligonucleotides, designed on the basis of sequence information provided herein, as probes or primers. Nucleic acid isolated and/or purified from one or more cells of a plant (see above), or a nucleic acid library derived from nucleic acid isolated and/or purified from the plant (e.g. a 20 cDNA library derived from mRNA isolated from the plant), may 25 be probed under conditions for selective hybridisation and/or subjected to a specific nucleic acid amplification reaction such as the polymerase chain reaction (PCR). The nucleic acid probed or used as template in the amplification reaction may

be genomic DNA, cDNA or RNA. If necessary, one or more gene fragments may be ligated to generate a full-length coding sequence.

- 5 PCR primers derived from the VRN2 sequences disclosed herein may readily be tested for their specificity for amplifying nucleic acid according to the present invention, using both genomic DNA and RT-PCR templates. Cloning and subsequent sequencing of PCR products may be used to indicate
- 10 amplification of the expected derived gene fragment. Full length cDNA clones can be obtained as described by 5' and 3' RACE technology if RT-PCR products are used as templates.

- Various aspects of the present invention include the
- 15 obtainable nucleic acid, methods of screening material, e.g. cell lysate, nucleic acid preparations, for the presence of nucleic acid of interest, methods of obtaining the nucleic acid, and suitable primers and primer combinations.
- 20 The sequence information provided herein also allows the design of diagnostic tests for determination of the presence of a specific gene or allele thereof in any given plant, cultivar, variety, population, landrace, part of a family or other selection in a breeding programme or other such
- 25 genotype. A diagnostic test may be based on determination of the presence or absence of a particular allele by means of nucleic acid or polypeptide determination.

At the nucleic acid level, this may involve hybridisation of a



suitable oligo- or poly-nucleotide, such as a fragment of the gene or a homologue thereof, including any homologue disclosed herein, or any particular allele, such as an allele which gives a desirable phenotype, such as any such allele disclosed  
5 herein. The hybridisation may involve PCR designed to amplify a product from a given allelic version of the gene, with subsequent detection of an amplified product by any of a number of possible methods including but not limited to gel electrophoresis, capillary electrophoresis, direct  
10 hybridisation of nucleotide sequence probes and so on. A diagnostic test may be based on PCR designed to amplify various alleles or any allele from the relevant locus, with a test to distinguish the different possible alleles by any of a number of possible methods, including DNA fragment size,  
15 restriction site variation (e.g. CAPS - cleaved amplified polymorphic sites) and so on. A diagnostic test may also be based on a great number of possible variants of nucleic acid analysis that will be apparent to those skilled in the art, such as use of a synthetic sequence as a hybridisation probe.

20

Broadly, the methods divide into those screening for the presence of nucleic acid sequences and those that rely on detecting the presence or absence of a polypeptide. The methods may make use of biological samples from one or more  
25 plants or cells that are suspected to contain the nucleic acid sequences or polypeptide.

Exemplary approaches for detecting nucleic acid or polypeptides include analysing a sample from the plant or

plant cell by:

(a) comparing the sequence of nucleic acid in the sample with all or part of a nucleotide sequence shown herein, to  
5 determine whether the sample contains a mutation;

(b) determining the presence in the sample of a polypeptide including a VRN2 amino acid sequence shown herein, or a fragment thereof and, if present, determining whether the  
10 polypeptide is full length, and/or is mutated, and/or is expressed at the normal level;

(c) performing DNA fingerprinting to compare the restriction pattern produced when a restriction enzyme cuts nucleic acid  
15 in the sample with the restriction pattern obtained from a nucleotide sequence shown herein, or from a known mutant, allele or variant thereof;

(d) contacting the sample with a specific binding member  
20 capable of binding to nucleic acid including the nucleotide sequence as set out herein, or a fragment thereof, or a mutant, allele or variant thereof, the specific binding member including nucleic acid hybridisable with a VRN2 sequence herein, or a polypeptide including a binding domain with  
25 specificity for nucleic acid including a VRN2 sequence or polypeptide encoded by it, or a mutated form thereof, and determining binding of the specific binding member;

(e) performing PCR involving one or more primers based on a

nucleotide sequence shown herein to screen the sample for nucleic acid including the nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO: 4 or a mutant, allele or variant thereof.

- 5 When screening for a VRN2 allele nucleic acid, the nucleic acid in the sample will initially be amplified, e.g. using PCR, to increase the amount of the analyte as compared to other sequences present in the sample. This allows the target sequences to be detected with a high degree of sensitivity if
- 10 they are present in the sample. This initial step may be avoided by using highly sensitive array techniques that are becoming increasingly important in the art.

- A variant form of the gene may contain one or more insertions,
- 15 deletions, substitutions and/or additions of one or more nucleotides compared with the wild-type sequence which may or may not disrupt or alter the gene function. Differences at the nucleic acid level are not necessarily reflected by a difference in the amino acid sequence of the encoded
- 20 polypeptide. However, a mutation or other difference in a gene may result in a frame-shift or stop codon, which could seriously affect the nature of the polypeptide produced (if any), or a point mutation or gross mutational change to the encoded polypeptide, including insertion, deletion,
- 25 substitution and/or addition of one or more amino acids or regions in the polypeptide. A mutation in a promoter sequence or other regulatory region may prevent or reduce expression from the gene or affect the processing or stability of the mRNA transcript.

Tests may be carried out on preparations containing genomic DNA, cDNA and/or mRNA. Testing cDNA or mRNA has the advantage of the complexity of the nucleic acid being reduced by the absence of intron sequences, but the possible disadvantage of extra time and effort being required in making the preparations. RNA is more difficult to manipulate than DNA because of the wide-spread occurrence of RN'ases.

Nucleic acid in a test sample may be sequenced and the sequence compared with a sequence shown herein to determine whether or not a difference is present. If so, the difference can be compared with known alleles to determine whether the test nucleic acid contains one or more of the variations indicated, or the difference can be investigated for association with a desired phenotype.

The amplified nucleic acid may then be sequenced as above, and/or tested in any other way to determine the presence or absence of a particular feature. Nucleic acid for testing may be prepared from nucleic acid removed from cells or in a library using a variety of other techniques such as restriction enzyme digest and electrophoresis.

Nucleic acid may be screened using a variant- or allele-specific probe. Such a probe corresponds in sequence to a region of the gene, or its complement, containing a sequence alteration known to be associated with alteration of ability to affect vernalization response, flowering time, leaf shape and/or shade avoidance response. Under suitably stringent

conditions, specific hybridisation of such a probe to test nucleic acid is indicative of the presence of the sequence alteration in the test nucleic acid. For efficient screening purposes, more than one probe may be used on the same test sample.

Allele- or variant-specific oligonucleotides may similarly be used in PCR to specifically amplify particular sequences if present in a test sample. Assessment of whether a PCR band contains a gene variant may be carried out in a number of ways familiar to those skilled in the art. The PCR product may for instance be treated in a way that enables one to display the mutation or polymorphism on a denaturing polyacrylamide DNA sequencing gel, with specific bands that are linked to the gene variants being selected.

An alternative or supplement to looking for the presence of variant sequences in a test sample is to look for the presence of the normal sequence, e.g. using a suitably specific oligonucleotide probe or primer.

Approaches which rely on hybridisation between a probe and test nucleic acid and subsequent detection of a mismatch may be employed. Under appropriate conditions (temperature, pH etc.), an oligonucleotide probe will hybridise with a sequence which is not entirely complementary. The degree of base-pairing between the two molecules will be sufficient for them to anneal despite a mis-match. Various approaches are well known in the art for detecting the presence of a mis-match

between two annealing nucleic acid molecules.

For instance, RN'ase A cleaves at the site of a mis-match. Cleavage can be detected by electrophoresing test nucleic acid to which the relevant probe or probe has annealed and looking for smaller molecules (i.e. molecules with higher electrophoretic mobility) than the full length probe/test hybrid. Other approaches rely on the use of enzymes such as resolvases or endonucleases.

10

Thus, an oligonucleotide probe that has the sequence of a region of the normal gene (either sense or anti-sense strand) in which mutations associated with particular phenotypes are known to occur may be annealed to test nucleic acid and the presence or absence of a mis-match determined. Detection of the presence of a mis-match may indicate the presence in the test nucleic acid of a mutation. On the other hand, an oligonucleotide probe that has the sequence of a region of the gene including a mutation may be annealed to test nucleic acid and the presence or absence of a mis-match determined. The presence of a mis-match may indicate that the nucleic acid in the test sample has the normal sequence, or a different mutant or allele sequence. In either case, a battery of probes to different regions of the gene may be employed.

25

The presence of differences in sequence of nucleic acid molecules may be detected by means of restriction enzyme digestion, such as in a method of DNA fingerprinting where the restriction pattern produced when one or more restriction

enzymes are used to cut a sample of nucleic acid is compared with the pattern obtained when a sample containing the normal gene or a variant or allele is digested with the same enzyme or enzymes.

5

The presence or absence of a lesion in a promoter or other regulatory sequence may also be assessed by determining the level of mRNA production by transcription or the level of polypeptide production by translation from the mRNA.

10

Nucleic acid isolated and/or purified from one or more cells of a plant or a nucleic acid library derived from nucleic acid isolated and/or purified from cells (e.g. a cDNA library derived from mRNA isolated from the cells), may be probed under conditions for selective hybridisation and/or subjected to a specific nucleic acid amplification reaction such as the polymerase chain reaction (PCR).

20

A method may include hybridisation of one or more (e.g. two) probes or primers to target nucleic acid. Where the nucleic acid is double-stranded DNA, hybridisation will generally be preceded by denaturation to produce single-stranded DNA. The hybridisation may be as part of a PCR procedure, or as part of a probing procedure not involving PCR. An example procedure would be a combination of PCR and low stringency hybridisation. A screening procedure, chosen from the many available to those skilled in the art, is used to identify successful hybridisation events and isolate hybridised nucleic acid.

Binding of a probe to target nucleic acid (e.g. DNA) may be measured using any of a variety of techniques at the disposal of those skilled in the art. For instance, probes may be radioactively, fluorescently or enzymatically labelled. Other  
5 methods not employing labelling of probe include examination of restriction fragment length polymorphisms, amplification using PCR, RNAase cleavage and allele specific oligonucleotide probing.

- 10 Probing may employ the standard Southern blotting technique. For instance DNA may be extracted from cells and digested with different restriction enzymes. Restriction fragments may then be separated by electrophoresis on an agarose gel, before denaturation and transfer to a nitrocellulose filter.
- 15 Labelled probe may be hybridised to the DNA fragments on the filter and binding determined. DNA for probing may be prepared from RNA preparations from cells.

- Preliminary experiments may be performed by hybridising under  
20 low stringency conditions various probes to Southern blots of DNA digested with restriction enzymes. Suitable conditions would be achieved when a large number of hybridising fragments were obtained while the background hybridisation was low. Using these conditions nucleic acid libraries, e.g. cDNA  
25 libraries representative of expressed sequences, may be searched.

As noted, those skilled in the art are well able to employ suitable conditions of the desired stringency for selective



hybridisation, taking into account factors such as oligonucleotide length and base composition, temperature and so on.

- 5 In some preferred embodiments of diagnostic assays according to the present invention, oligonucleotides according to the present invention that are fragments of any of the sequences shown herein, or any allele associated with a desired phenotype are at least about 10 nucleotides in length, more  
10 preferably at least about 15 nucleotides in length, more preferably at least about 20 nucleotides in length, more preferably about 30 nucleotides in length. Such fragments themselves individually represent aspects of the present invention. Fragments and other oligonucleotides may be used  
15 as primers or probes as discussed but may also be generated (e.g. by PCR) in methods concerned with determining the presence in a test sample of a sequence indicative of a desired phenotype.

20

There are various methods for determining the presence or absence in a test sample of a particular polypeptide, such as a polypeptide including the amino acid sequence shown in SEQ ID NO: 2 or SEQ ID NO: 5, or an amino acid sequence mutant,  
25 variant or allele thereof.

A sample may be tested for the presence of a binding partner for a specific binding member such as an antibody (or mixture of antibodies), specific for one or more particular variants

of a polypeptide shown herein.

In such cases, the sample may be tested by being contacted with a specific binding member such as an antibody under appropriate conditions for specific binding, before binding is determined, for instance using a reporter system as discussed. Where a panel of antibodies is used, different reporting labels may be employed for each antibody so that binding of each can be determined.

10

A specific binding member such as an antibody may be used to isolate and/or purify its binding partner polypeptide from a test sample, to allow for sequence and/or biochemical analysis of the polypeptide to determine whether it has the sequence and/or properties of the wild-type polypeptide or a particular mutant, variant or allele thereof. Amino acid sequence is routine in the art using automated sequencing machines.

20 The use of diagnostic tests for alleles allows the researcher or plant breeder to establish, with full confidence and independent from time consuming biochemical tests, whether or not a desired allele is present in the plant of interest (or a cell thereof), whether the plant is a representative of a collection of other genetically identical plants (e.g. an inbred variety or cultivar) or one individual in a sample of related (e.g. breeders' selection) or unrelated plants.

In a breeding scheme based on selection and selfing of

desirable individuals, nucleic acid or polypeptide diagnostics for the desirable allele or alleles in high throughput, low cost assays as provided by this invention, reliable selection for the can be made at early generations and on more material than would otherwise be possible. This gain in reliability of selection plus the time saving by being able to test material earlier and without costly phenotype screening is of considerable value in plant breeding.

- 10 Nucleic acid-based determination of the presence or absence of one or more desirable alleles may be combined with determination of the genotype of the flanking linked genomic DNA and other unlinked genomic DNA using established sets of markers such as RFLPs, microsatellites or SSRs, AFLPs, RAPDs etc. This enables the researcher or plant breeder to select for not only the presence of the desirable allele but also for individual plant or families of plants which have the most desirable combinations of linked and unlinked genetic background. Such recombinations of desirable material may occur only rarely within a given segregating breeding population or backcross progeny. Direct assay of the locus as afforded by the present invention allows the researcher to make a stepwise approach to fixing (making homozygous) the desired combination of flanking markers and alleles, by first identifying individuals fixed for one flanking marker and then identifying progeny fixed on the other side of the locus all the time knowing with confidence that the desirable allele is still present.

The present disclosure provides sufficient information for a person skilled in the art to obtain genomic DNA sequence for any given new or existing allele and devise a suitable nucleic acid- and/or polypeptide-based diagnostic assay. In designing  
5 a nucleic acid assay account is taken of the distinctive variation in sequence that characterises the particular variant allele.

Nucleic acid according to the invention may include a  
10 nucleotide sequence encoding a product involved in vernalization response, flowering time, leaf shape and/or shade avoidance response. Reducing or increasing the level of expression may be used to manipulate such a characteristic in a plant. This may involve use of anti-sense or sense  
15 regulation, discussed further below.

Nucleic acid according to the invention, such as a *VRN2* gene or homologue, may be placed under the control of an externally inducible gene promoter to place expression under the control  
20 of the user. An advantage of introduction of a heterologous gene into a plant cell, particularly when the cell is comprised in a plant, is the ability to place expression of the gene under the control of a promoter of choice, in order to be able to influence gene expression, and therefore  
25 vernalization response, flowering time, leaf shape, shade avoidance response, and/or other characteristic, according to preference. Furthermore, mutants and derivatives of the wild-type gene, e.g. with higher or lower activity than wild-type, may be used in place of the endogenous gene.

In the present invention, over-expression may be achieved by introduction of the nucleotide sequence in a sense orientation. Thus, the present invention provides a method of influencing a physical characteristic of a plant, the method including causing or allowing expression of the product (polypeptide or nucleic acid transcript) encoded by heterologous nucleic acid according to the invention from that nucleic acid within cells of the plant.

10 Down-regulation of expression of a target gene may be achieved using anti-sense technology or "sense regulation" ("co-suppression").

In using anti-sense genes or partial gene sequences to down-regulate gene expression, a nucleotide sequence is placed under the control of a promoter in a "reverse orientation" such that transcription yields RNA which is complementary to normal mRNA transcribed from the "sense" strand of the target gene. See, for example, Rothstein et al, 1987; Smith et al, (1988) *Nature* 334, 724-726; Zhang et al, (1992) *The Plant Cell* 4, 1575-1588, English et al., (1996) *The Plant Cell* 8, 179-188. Antisense technology is also reviewed in Bourque, (1995), *Plant Science* 105, 125-149, and Flavell, (1994) *PNAS USA* 91, 3490-3496.

25

An alternative is to use a copy of all or part of the target gene inserted in sense, that is the same, orientation as the target gene, to achieve reduction in expression of the target gene by co-suppression. See, for example, van der Krol et

al., (1990) *The Plant Cell* 2, 291-299; Napoli et al., (1990) *The Plant Cell* 2, 279-289; Zhang et al., (1992) *The Plant Cell* 4, 1575-1588, and US-A-5,231,020.

5 The complete sequence corresponding to the coding sequence (in reverse orientation for anti-sense) need not be used. For example fragments of sufficient length may be used. It is a routine matter for the person skilled in the art to screen fragments of various sizes and from various parts of the  
10 coding sequence to optimise the level of anti-sense inhibition. It may be advantageous to include the initiating methionine ATG codon, and perhaps one or more nucleotides upstream of the initiating codon. A further possibility is to target a conserved sequence of a gene, e.g. a sequence that is  
15 characteristic of one or more genes, such as a regulatory sequence.

The sequence employed may be about 500 nucleotides or less, possibly about 400 nucleotides, about 300 nucleotides, about  
20 200 nucleotides, or about 100 nucleotides. It may be possible to use oligonucleotides of much shorter lengths, 14-23 nucleotides, although longer fragments, and generally even longer than about 500 nucleotides are preferable where possible, such as longer than about 600 nucleotides, than  
25 about 700 nucleotides, than about 800 nucleotides, than about 1000 nucleotides or more.

It may be preferable that there is complete sequence identity in the sequence used for down-regulation of expression of a

target sequence, and the target sequence, though total complementarity or similarity of sequence is not essential. One or more nucleotides may differ in the sequence used from the target gene. Thus, a sequence employed in a down-

5 regulation of gene expression in accordance with the present invention may be a wild-type sequence (e.g. gene) selected from those available, or a mutant, derivative, variant or allele, by way of insertion, addition, deletion or substitution of one or more nucleotides, of such a sequence.

10 The sequence need not include an open reading frame or specify an RNA that would be translatable. It may be preferred for there to be sufficient homology for the respective anti-sense and sense RNA molecules to hybridise. There may be down regulation of gene expression even where there is about 5%,  
15 10%, 15% or 20% or more mismatch between the sequence used and the target gene.

Generally, the transcribed nucleic acid may represent a fragment of a gene, or the complement thereof, or may be a  
20 mutant, derivative, variant or allele thereof, in similar terms as discussed above in relation to alterations being made to a coding sequence and the homology of the altered sequence. The homology may be sufficient for the transcribed anti-sense RNA to hybridise with nucleic acid within cells of the plant,  
25 though irrespective of whether hybridisation takes place the desired effect is down-regulation of gene expression.

Thus, the present invention also provides a method of modifying, affecting, altering or modulating a characteristic

of a plant, e.g. vernalization response, flowering time, leaf shape and/or shade avoidance response, the method including causing or allowing anti-sense transcription from heterologous nucleic acid according to the invention within cells of the  
5 plant.

The present invention further provides the use of the nucleotide sequence of *VRN2*, or a fragment, mutant, derivative, allele, variant or homologue thereof for down-  
10 regulation of gene expression, particularly down-regulation of expression of a *VRN2* gene or homologue thereof, preferably in order to influence a physical characteristic of a plant, especially vernalization response, flowering time, leaf shape and/or shade avoidance response.

15 When additional copies of the target gene are inserted in sense, that is the same, orientation as the target gene, a range of phenotypes is produced which includes individuals where over-expression occurs and some where under-expression  
20 of protein from the target gene occurs. When the inserted gene is only part of the endogenous gene the number of under-expressing individuals in the transgenic population increases. The mechanism by which sense regulation occurs, particularly down-regulation, is not well-understood.

25 However, this technique is also well-reported in scientific and patent literature and is used routinely for gene control. See, for example, van der Krol et al., (1990) *The Plant Cell* 2, 291-229; Napoli et al., (1990) *The Plant Cell* 2, 279-289; Zhang et al, 1992 *The Plant Cell* 4, 1575-1588.



Again, fragments, mutants and so on may be used in similar terms as described above for use in anti-sense regulation.

Thus, the present invention also provides a method of

5 influencing a characteristic of a plant, e.g. vernalization response, flowering time, leaf shape and/or shade avoidance response, the method including causing or allowing expression from nucleic acid according to the invention within cells of the plant. This may be used to suppress activity of a product  
10 with ability to influence vernalization response, flowering time, leaf shape and/or shade avoidance response. Here the activity of the product is preferably suppressed as a result of under-expression within the plant cells.

15

Aspects and embodiments of the present invention will now be illustrated, by way of example, with reference to the accompanying figures. Further aspects and embodiments will be  
20 apparent to those skilled in the art. All documents mentioned in this text are incorporated herein by reference.

#### *BRIEF DESCRIPTION OF THE FIGURES*

Figure 1 shows total leaf number (Rosette plus Cauline) of *Ler*  
25 plants (squares), *fca-1* plants (diamonds) and *vrn2-1 fca-1* plants (circles) after various periods of vernalization (measured in days).

Figure 2 illustrates the Red Far-Red Light plant phenotype:

Figure 2A shows the area of the largest leaf of *Ler*, *fca-1* and *vrn2-1 fca-1* plants grown under white light (W) (open bars) or white light with supplementary FR light (W + FR) (shaded bars).

5 Figure 2B shows the rosette leaf number at bolting of plants treated as in the experiment of which results are shown in Figure 2A.

Figure 3 illustrates results of genetic and physical mapping  
10 of *VRN2* in *Arabidopsis thaliana*.

Figure 4 illustrates cosmids and genes near *VRN2* in the *Arabidopsis* genome.

15 Figure 5 illustrates the structure of the *VRN2* gene of *Arabidopsis*, the 5K cDNA aberrant splicing, and the position and nature of the *vrn2-1* mutation. Exons are shown as open boxes. Untranslated regions are shown as shaded boxes. Introns are shown as lines.

20 Figure 6 shows the sequence of *VRN2* cDNA, including coding sequence and predicted amino acid sequence of the encoded protein. Putative NLSs are boxed, the putative acidic activation domain is underlined. The putative zinc-finger  
25 motif is doubly underlined. The positions of introns are indicated with arrows. The position of the *vrn2-1* mutation is circled.

Figure 7 illustrates dCAPS Marker for the *vrn2-1* Mutation. A

diagnostic derived CAPS (dCAPS) marker was designated for the  
 vrn2-1 mutation. This utilizes a primer (VRN2-AZ) that  
 includes half of the recognition site for the XmnI restriction  
 enzyme, the other half is supplied, specifically, by the  
 5 sequence of the vrn2-1 mutation. This results in a successful  
 restriction digestion only when using PCR amplified genomic  
 DNA from vrn2-1 mutants as a template.

Figure 8 shows alignment of the *Arabidopsis* VRN2 amino acid  
 10 sequence with similar proteins.

Figure 8A aligns the full-length VRN2 protein with four  
 other proteins, using Clustal method with PAM250 residue  
 weight table, performed on 17 January 1999 at 19:19 GMT.

Figure 8B aligns the zinc finger region, using Clustal  
 15 method with PAM250 residue weight table, performed on 17  
 January 1999 at 19:25 GMT.

#### Abbreviations:

At *Arabidopsis thaliana*, Sc *Saccharomyces cerevisiae*, Sp  
 20 *Schizosaccharomyces pombe*, Ce *Caenorhabditis elegans*, Dm  
*Drosophila melanogaster*, Hs *Homo sapiens*, Mm *Mus musculus*, Rn  
*Rattus norvegicus*, Xm *Xiphophorus maculatus*.

#### LIST OF SEQUENCES

25

SEQ ID NO: \SEQUENCE

- 1 Landsberg erecta VRN2 cDNA
- 2 Landsberg erecta VRN2 amino acid

- 3 Landsberg erecta VRN2 genomic
- 4 Columbia VRN2 cDNA
- 5 Columbia VRN2 amino acid
- 6 Columbia VRN2 genomic
- 5 7 5K (Columbia, abberant splice) cDNA
- 8 5K (Columbia, abberant splice) amino acid
- 9 C72616 EST (modified) cDNA
- 10 C72616 EST (modified) amino acid
- 11 AI163743 EST (modified) cDNA
- 10 12 AI163743 EST (modified) amino acid
- 13 At Hyp 2245035 (ATFCA7\_4) (modified) cDNA
- 14 At Hyp 2245035 (ATFCA7\_4) (modified) amino acid
- 15 KIAA0160 cDNA
- 16 KIAA0160 amino acid

15

Additional sequences included in the Figures:

- 17 Landsberg erecta VRN2 zinc finger amino acid
- 18 At Di19 S51478 zinc finger 1 amino acid
- 20 19 At Di19 S54178 zinc finger 2 amino acid
- 20 At SUP U38946 zinc finger amino acid
- 21 At Hyp 2191171 zinc finger amino acid
- 22 At Hyp 3377806 zinc finger amino acid
- 23 Sc Pep7 91500 zinc finger amino acid
- 25 24 Sc TFIIIA 730931 zinc finger amino acid
- 25 Sp Hyp 1351713 zinc finger amino acid
- 26 Ce Hyp 255942 zinc finger amino acid
- 27 Ce Hyp 2854197 zinc finger amino acid
- 28 Ce Hyp 304459 zinc finger amino acid

- 29 Dm BRCORE-NS-Z3 zinc finger amino acid  
 30 Dm GAGA 729556 zinc finger amino acid  
 31 Dm ken 3550814 zinc finger amino acid  
 32 Hs ATBF-1 976347 zinc finger amino acid  
 5 33 Hs KIAA0160 zinc finger amino acid  
 34 Hs ZNF142 3123312 zinc finger amino acid  
 35 Mm FOG 2252814 zinc finger amino acid  
 36 Mm Spalt 1296845 zinc finger amino acid  
 37 Rn Roaz 2149792 zinc finger amino acid  
 10 38 Xm ZF1 532083 zinc finger amino acid

#### EXAMPLE 1

*Characterisation and Cloning of VRN of Arabidopsis Thaliana and Mutant Alleles Thereof*

15

#### Isolation of vrn2 mutants

Two vrn2 mutant alleles (vrn2-1 and vrn2-2) were isolated by mutagenising fca-1 seeds with EMS as described by Chandler et al. (Plant J (1996) 10: 637-644). WO96/38560 (PCT/GB96/01332) discloses the sequence of fca and mutant alleles and their cloning and characterisation. The vrn2-1 fca-1 line used here has been backcrossed to fca-1 four times. For mapping purposes, the vrn2-1 allele was used (at the 2nd backcross).

25

#### Phenotypic Characterization

##### *Vernalization*

The vernalization response of *vrn2* mutant plants was investigated by examining their flowering time in response to increasing durations of vernalization treatment.

- 5 Standard vernalization conditions were used, i.e. low light intensity  $5 \mu\text{mol m}^{-2} \text{s}^{-1}$ , 8 hr photoperiod,  $5 \pm 1$  degree C, for varying periods (from between 1 and 42 days). Similar effects would be observed under continuous or no light, the temperature is more important.

10

- In the absence of a vernalization treatment, *vrn2-1 fca-1* mutant plants showed a small but consistent delay in flowering compared to the parental (wild-type) *fca-1* controls (Figure 1). However, following vernalization, this difference was
- 15 greatly magnified (Figure 1). The response exhibited by *vrn2-1 fca-1* plants was typically a 35% reduction in total leaf number after 6 weeks of vernalization, compared to 67% reduction or *fca-1* controls. The delay in flowering, both with and without a vernalization treatment, as measured by
- 20 increased leaf number, was also observed if the days to flower i.e. the day at which the first floral bud was visible was used.

#### *Red/Far-Red light perception*

25

The response to vernalization in *Arabidopsis* has been positively correlated with the response to different ratios of Red(R) to Far-red(FR) light; mutants and ecotypes that respond strongly tend to respond strongly to conditions of low R:FR

(Bagnall, Ann Bot (1993) 71: 75-83; Martinez-Zapater et al., Plant Physiol (1990) 92: 770-776). This response typically manifests itself in two distinct ways - an acceleration of flowering time (leading to an effect that mimics the effect of a vernalization treatment) and a reduction in leaf area (or shade avoidance). This response is believed to have evolved to allow plants to adapt to the availability of light allowing individuals to seek light when in competition with their neighbors.

We examined the ability of *vrn2-1 fca-1* mutants to respond to conditions that mimic such an environment.

Under these conditions, *vrn2-1 fca-1* plants showed a marked reduction in the shade avoidance response, with the mean area of the largest leaf decreasing by only 26%, compared to 74% for the *fca-1* control (Figure 2A). However, the *vrn2-1* mutation does not appear to affect all aspects of the response to FR light, as *vrn2-1 fca-1* plants showed a similar acceleration of flowering in response to supplementary FR light as *fca-1* controls (Figure 2B).

These data provide indication that VRN2 plays a role in regulating the response to FR light, and may mediate changes specifically in leaf size (as flowering time is only slightly affected) under conditions of low R:FR ratios.

#### Genetic Mapping

The VRN2 gene was mapped in an F2 population derived from the cross *vrn2-1 fca-1* crossed to *fca-10*, following the procedure used to map the VRN1 gene (Chandler et al. *supra.*). The VRN2 gene was initially positioned using a population of 70 F2 individuals between the RFLP markers g13683 and mil12 (Schmidt et al., Plant J (1996) 9: 755-765) on the long arm of Chromosome IV (or D), using conventional techniques. The map position of VRN2 was further refined by screening an additional 429 F2 plants with a SSLP derived from the marker g19247 (Schmidt et al., (1996) Plant J 9: 755-765) and the CAPS marker g4539 (Parker et al., Plant Cell (1998) 9: 1-17). A total of 12 individual F2 plants that were recombinant between g19247 and g4539 were further analyzed with RFLP markers g13683 and CC36F6 (Bancroft et al., Weeds World 4ii:(1997)) and the CAPS marker C18 (Parket et al., *supra.*), and with two additional CAPS markers (VRN2RS, VRN2CD) generated using the published Columbia sequence (Bevan et al., Nature (1998) 391: 485-488) (accession numbers Z97341 and Z97342) as a template. The VRN2 gene was localized to a 245 kb region defined at the centromeric (north) end by an RFLP detected with the cosmid CC36F6, and at the telomeric (south) end by the g4539 CAPS marker. This interval is defined by 3 recombinant individual F2 plants; 1 recombinant between VRN2 and CC36F6, and 2 recombinants between g4539 and VRN2 (Figure 3).

#### Physical Mapping

The genetic interval defined by CC36F6 and g4539 is almost



completely covered by the 3 BAC clones T1C7, I5D3 and T5O15. Cosmids derived from subclones of YAC EW16B10 in the binary vector 04541 (Bancroft et al., supra.) (abbreviated as IB) were positioned by end sequencing, and ordered relative to the published sequence of the Columbia ecotype in this region (Genbank accession numbers Z97341 and Z97342). We selected cosmids clones that extended from the complex RPP5 locus outwards to CC36F6 and g4539, reasoning that VRN2 was not within the RPP5 locus, which is comprised of multiple repeats of RPP5-like genes in both Columbia and Landsberg ecotypes (Bevan et al., supra.).

Additional Landsberg cosmids in the 04541 binary vector covering the region not covered by the Columbia YAC subclone cosmids were identified by hybridization to the inserts from BACs T1C7 and T5O15, and aligned based on end sequencing, and compared to the published Columbia sequence (Bevan et al., supra.) and to the sequence of the Landsberg ecotype in this region. An almost complete cosmid contig was generated over this region.

Simultaneously with the isolation of cosmids, ordered cosmids, beginning with those at the centromeric end of the contig, were transformed into *vrn2-1 fca-1* plants by *Agrobacterium tumefaciens*-mediated vacuum infiltration (Bechtold et al., C R Acad Sci Paris (1993) 316: 1194-1199). (Figure 3). The presence of the cosmid in each transgenic line (T1 plants) was confirmed by a cosmid-specific diagnostic PCR, comprising an insert specific primer (corresponding to a portion of the

Columbia genomic DNA) and a primer present in the cosmid vector.

#### Cosmid Complementation

5  
Cosmids introduced into *vrn2-1 fca-1* plants were tested for their ability to complement the *vrn2* phenotype. T2 seeds, from individual T1 plants segregating kanamycin resistance at a 3:1 ratio, were sown on soil and vernalized for two (in some  
10 experiments three) weeks. Plants were then transferred to greenhouse conditions, and after ten days pricked out into individual compartments of divided trays. Total leaf number was determined, and cosmids were scored as complementing if the segregation ratio of early to late plants (when compared  
15 to *fca-1* and *vrn2-1 fca-1* controls) plants was approximately 3:1.

Two Columbia cosmids (4A23, 2 out of 2 T1s; 6N1, 1 out of 1 T1) clearly complemented the phenotype of *vrn2-1 fca-1*  
20 mutants, with the earliest plants flowering at approximately the same time as vernalized *fca-1* plants.

#### Sequence Analysis and ORF Prediction

25 The sequence in common to both IB4A23 and IB6N1 cosmids has previously been annotated as containing 2 complete predicted genes (ATDL4445W and ATDL4450W) and (presumably non-functional) portions of two other genes - the 3' end of ATDL4440W and the 3' end of the RPP5-like gene, CHPR

(ATDL4460W) (Bevan et al., *supra.*) Genbank accession number 297342. In addition, a cognate cDNA (5K) not included in the annotation is present in this region, and appears to span two of the predicted genes (ATDL4445W and ATDL4450W) (Bevan et

5 al., *supra.*). However, as two cosmids in the region (1 independent T1 line from each of cosmids IB4N6 and IB6C5) did not complement the mutant phenotype (Figure 4) this ruled out the predicted gene ATDL4445W. This left the unannotated cDNA 5K, and the predicted gene ATDL4450W as candidates for VRN2.

10 However, the presence the cognate cDNA 5K from the Columbia ecotype that overlapped both ATDL4445W and ATDL4450W necessitated a re-examination of the prediction for the ATDL4450W gene.

15 In order to define the structure of these genes, we used the NetGene2 prediction program (Hebsgaard et al., Nucl Acids Res (1998) 24: 3439-3452), using "Arabidopsis" as the organism option (the only parameter that can be set manually). BLAST, PSI-BLAST, PSORT and PROSITE programs were used to identify  
20 potential function domains and similarities (Altschul et al., Nucleic Acids Res (1997) 25: 3389-3402; Bairoch et al., Nucl Acids Res (1997) 25: 217-221; Nakai et al., Genomics (1992) 14: 897-911). Default parameters of TBLASTN, PSI-BLAST and BLASTP were used (Expect = 10, BLOSUM62 matrix, gap penalty =  
25 11, penalty per gap 1, lambda ratio 0.85). The NCBI/GenBank database was used. The PSORT algorithm (Nakai) was used, using the "plant" option as the source organism (the only parameter that can be manually changed). The Profile Scan program at PROSITE (Bairoch) was used to search for motifs in

VRN2, with default parameters (there are no parameters a user can select, the results being "hit" or "no hit").

This analysis yielded predictions for two genes, 5K, a putative nuclear localized protein that is highly post-transcriptionally spliced (15 exons), represented by the Columbia cognate cDNA; and a modified prediction for 4450, with 6 putative membrane-spanning domains, represented at its 3' end by an Arabidopsis EST (accession number T22412).

10

Determination of the *vrn2-1* Mutation and Identification of the VRN2 gene

In an attempt to determine which gene (5K or 4450) is VRN2, PCR primers were designed to amplify products encompassing the entire predicted open reading frame of both genes.

Three independent RT-PCR reactions using total RNA prepared from *fca-1, vrn2-1 fca-1* and *vrn2-2 fca-1* 14 day-old seedlings grown on GM plates in continuous light were performed for each predicted gene with a high fidelity enzyme mix (Boehringer Mannheim, HiFi System). These PCR products were sequenced using both the primers used for PCR, and a series of internal primers, using the BIGDYE kit (PE Applied Biosystems). The reactions were run on an ABI377 machine, and compiled using the SeqMan (DNASTar, Lasergene) program.

The sequences of the PCR confirmed our prediction for both genes, and indicated that we had amplified across the entire

open reading frame of 5K and ATDL4450W as anticipated.

Several minor polymorphic differences were detected between the published Columbia sequence, and the Landsberg erecta sequence we amplified by PCR. These differences were consistent with the Landsberg erecta genomic sequence in this region. Furthermore, the Columbia cDNA for 5K appears to utilise a different splice donor site from that used in the Landsberg ecotype, and would produce a truncated, presumably non-functional protein (Figure 5). However, we have also sequenced the Columbia 5K product derived independently by RT-PCR, and this appears to use the same splice site as Landsberg, and should encode a functional protein. A consistent difference between the *vrn2* mutants and *fca-1* was detected in the 5K PCR product, a G to A change at position 1201 of the predicted cDNA in *vrn2-1 fca-1* (Figure 5). We are currently investigating the nature of the mutation in the *vrn2-2* allele. This type of mutation, a single base-pair change, is commonly observed following EMS mutagenesis. This mutation converts a TGG codon (Tryptophan) to stop codon (TGA), and would result in the production of a truncated protein of 322 amino acids in the *vrn2-1* mutant, compared to 443 amino acids of wild type VRN2 (Figure 6). The presence of this mutation indicated that 5K was likely to be VRN2. The presence of the *vrn2-1* mutation in the genome of *vrn2-1 fca-1* mutant plants was confirmed by a derived CAPS (dCAPS) (Michaels et al., Plant J (1998) 14: 381-385; Neff et al., Plant J (1998) 14: 387-392) marker specific for the *vrn2-1* mutation (Figure 7). This diagnostic test is specific for the

*vrn2-1* mutation, as it detects wild type VRN2 in both *fca-1* and *vrn2-2 fca-1* mutants.

#### Analysis of the VRN2 gene

5

To gain an insight into the possible function of the VRN2 gene, and how the *vrn2-1* mutation may affect the function of the VRN2 protein, we compared the amino acid sequence of VRN2 to several databases of protein and translated nucleic acid sequences using BLASTP and TBLASTN programs at NCBI, using the default parameters as noted above.

Several molecules with a significant degree of similarity were identified (Table 1 and Table 2).

15

One such gene, represented by a human cDNA (KIAA0160) shares homology with VRN2 over a short region near the amino terminus of VRN2 (amino acids 63 to 132), and a longer, but less conserved region of homology towards the carboxy terminus (amino acids 263-366) (Figure 8a). Closer examination of the amino terminal conserved region revealed that it matches the consensus of a zinc-finger motif. Such motifs can take a variety of forms, but all co-ordinate zinc atoms through two cysteine residues, and two cysteine or histidine residues.

VRN2 falls into the latter class, having a C2H2 motif comprised of two cysteines separated by 2 amino acids, and two histidines separated by two amino acids (Mackay et al., TIBS (1998) 23: 1-4) .

Zinc-finger motifs are known to be capable of mediating both protein-DNA and protein-protein interactions. The zinc finger motif of VRN2 does not closely resemble the large EPF family of *Arabidopsis* C2H2 zinc fingers from *Arabidopsis*, which have  
5 a highly conserved QALGG motif in the middle of the zinc finger (Kubo et al., Nucl Acids Res (1998) 26: 608-615) (Figure 8b). In addition, VRN2 differs from the EPF proteins in that VRN2 has a single zinc finger motif, whereas most members of the EPF family (with the exception of SUP and AtZFP1) have  
10 between two and four zinc fingers (Kubo et al., supra.). This amino-terminal region (amino acids 63-132), and particularly the zinc-finger motif (amino acids 90-111) may thus represent a domain that mediates protein-protein or protein-DNA interactions.

15

The carboxy terminus of VRN2 (amino acids 263 to 366) is similar to several other candidate genes (Table 1 and Table 2). As mentioned above, there is limited homology to the human predicted protein KIAA0160. The molecule showing  
20 greatest homology to VRN2 is an EST sequence from poplar (*Populus tremula* L. x *Populus tremuloides* Michx (Accession Number AI163743) (Sterky et al., PNAS USA (1998) 95: 13330-13335) which has 52.8% identity over 127 amino acids (Table 1), as calculated with the BLASTP algorithm using  
25 default parameters (as noted above). VRN2 also shows significant similarity to a predicted *Arabidopsis* protein (ATFCA7\_4, Accession Number 2245035) (Bevan et al., supra.), which is quite close to VRN2 on chromosome 4, only 30 kb away towards the centromere. A close examination of the sequence

near this gene revealed that the prediction as annotated may be incorrect, as the use of a different splice site, resulting a different carboxy terminus to the protein, increases the degree of homology with VRN2. The similarity of these two

5 *Arabidopsis* genes raises the possibility that VRN2 may be a member of a gene family in *Arabidopsis*, and their close position suggests that these genes may have arisen following a duplication. Arguing against this notion is the observation that these two genes, VRN2 and ATFCA7\_4, are transcribed in

10 opposite directions. A rice EST (C72616) also shares significant similarity with the carboxyl region of VRN2, suggesting that this region may form an evolutionarily conserved domain present in monocots and dicots.

15 This conserved carboxy region is predicted to be highly charged, as it is composed of a large number of acidic residues (D and E). This highly charged region is highly similar in the Poplar and rice ESTs (Table 2). Such acidic regions are found in a number of eukaryotic transcription

20 factors, and often function as activation domains (Hahn, Cell (1993) 72: 481-483). It is therefore possible that VRN2 may function as a transcription factor, given it has both a DNA-binding motif (or protein binding) (amino acids 63-132) and a putative activation domain (amino acids 263-328).

25 Furthermore, the amino portion of VRN2 contains two predicted nuclear localization signals (NLSs) (Figure 6). The first is a simple 4 residue basic signal, while the second is a bi-partite signal, that fits the consensus (R/K) (R/K) N10 (R/K) 4 (Dingwall et al., TIBS (1991) 16: 478-481).



*EXAMPLE 2**Production and Characterisation of Arabidopsis Transgenic for VRN2*

- 5 VRN2 cDNA in the sense orientation is cloned into plant expression vectors SLJ4D4 and SLJ4K1 (Jones et al., (1992) Transg. Res. 1, pp 285-297) according to the teaching of Sambrook J et al (1989) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. SLJ4D4 and SLJ4K1 place the VRN2 cDNA under the control of the Ca MV 35S promoter and include terminator sequences from octopine synthase (ocs) and nopaline synthase (nos) genes, respectively.
- 10
- 15 Antisense constructs are produced in the same manner except that the VRN2 cDNA is inserted into the expression vectors in the opposite orientation.
- 20 The VRN2 expression cassettes are then subcloned separately into the binary vector SLJ1714 (Jones et al., *supra*), and mobilised into *Agrobacterium* strains by tri-parental mating according to the teaching of Hoekema et al., (1983) Nature 303, pp 179-180. *Arabidopsis* are transformed with the *Agrobacterium* strains carrying VRN2 expression constructs
- 25 (either sense or antisense) following the teaching of Bechtold et al., (1993) C R Acad. Sci. Paris 316, pp 1194-1199.

*Arabidopsis* plants are assayed for changes in their response to changes in the ratio of far red light, essentially as

described by Halliday et al., (1997) Plant J. 12, pp 1079-1090.

### Results

5

Differences in vernalisation requirement and response are observed in *Arabidopsis* plants transgenic for VRN2 (sense or antisense orientation) relative to *Arabidopsis* plants transformed with empty vectors and non-transformed *Arabidopsis* plants.

### EXAMPLE 3

#### *Production and Characterisation of Tobacco Transgenic for VRN2*

15 VRN2 cDNA in the sense orientation is cloned into plant expression vectors SLJ4D4 and SLJ4K1 as described in Example 2.

Antisense constructs are produced in the same manner except 20 that the VRN2 cDNA is inserted into the expression vectors in the opposite orientation.

VRN2 expression cassettes subcloned separately into the binary vector SLJ1714 (Jones et al supra), are mobilised into 25 *Agrobacterium* strains by tri-parental mating as in Example 2, and tobacco plants are transformed using the *Agrobacterium* strains carrying VRN2 expression constructs (either sense or antisense) following the teaching of Horsch et al., (1985) Science 227, pp 1229-1231.

Tobacco plants are assayed for changes in their response to changes in the ratio of far red light, essentially as described by Halliday et al., (1997) Plant J. 12, pp 1079-1090.

5

### *Results*

Differences in vernalisation requirement and response are observed in Tobacco plants transgenic for VRN2 (sense or antisense orientation) relative to Tobacco plants transformed with empty vectors and non-transformed Tobacco plants.

### *EXAMPLE 4*

*Production and Characterisation of Brassica (Oil Seed Rape, Winter Type) Transgenic for VRN2*

Sense and antisense constructs are used to generate *Agrobacterium* strains carrying VRN2 expression constructs (either sense or antisense) as described in Example 2 and Example 3, and are used to transform oil seed rape following the teaching of Moloney et al., (1989) Plant Cell Rep. 8, pp 238-242.

### *Results*

25

Differences in vernalisation requirement and response are observed in oil seed rape plants transgenic for VRN2 (sense or antisense orientation) relative to oil seed rape plants transformed with empty vectors and non-transformed oil seed

rape plants.

#### EXAMPLE 5

##### *Production and Characterisation of Rice Transgenic for VRN2*

5

VRN2 cDNA in the sense or antisense orientation is cloned into constructs and used to generate respective *Agrobacterium* strains. The *Agrobacterium* strains carrying VRN2 expression constructs (either sense or antisense) are used to transform  
10 rice following the teaching of Kohll A et al (1998) Proc. Natl. Acad. Sci. USA 95, pp 7203-7208.

#### *Results*

15 Differences in vernalisation requirement and response are observed in rice plants transgenic for VRN2 (sense or antisense orientation) relative to rice plants transformed with empty vectors and non-transformed rice plants.

#### 20 EXAMPLE 6

##### *Production and Characterisation of Wheat Transgenic for VRN2*

*Agrobacterium* strains carrying VRN2 expression constructs (either sense or antisense) are generated as in preceding  
25 Examples and are used to transform wheat following the teaching of Becker D et al., (1994) Plant J. 5, pp 299-307.

#### *Results*

Differences in vernalisation requirement and response are observed in wheat plants transgenic for VRN2 (sense or antisense orientation) relative to wheat plants transformed with empty vectors and non-transformed wheat plants.

5

#### METHODS AND MATERIALS

##### Plant Growth

For vernalization treatments, seeds were sown on a damp layer of fine grit (Levington's M3) on wet soil in individual pots, and vernalized for increasing durations at 4°C, 8hr light:16hr dark, 5  $\mu\text{mol m}^{-2} \text{sec}^{-1}$  light intensity. Seed sowing was staggered, with all plants removed from the vernalization conditions simultaneously. Following vernalization, plants were placed into a controlled environment chamber (Gallenkamp), 20°C, 16 hr light: 8hr dark 90  $\mu\text{mol m}^{-2} \text{sec}^{-1}$  light intensity. Plants receiving no vernalization treatment were stratified for 2 days under vernalization conditions, and grown for two days prior to transfer into the growth cabinet. Plants were grown for 10 days, and then pricked out into individual compartments of P40 trays. The flowering time, as measured by counting total leaf number (i.e. rosette and cauline leaves) was determined once the primary inflorescence had elongated sufficiently.

25

The phenotype of *vrn2-1 fca-1* plants was examined under different ratios of red to far-red (R:FR) light. Plants were stratified for 2 days, then grown for 10 days under continuous light, and then transferred to separate growth chambers with

white light (W), R:FR ratio of 5.8, with or without  
 supplementary FR light (W+FR), R:FR ratio 0.08. The number of  
 rosette leaves was determined to measure flowering time, and  
 the area of the largest leaf was used as an indicator of the  
 5 shade-avoidance response.

### Mapping

VRN2 was positioned on the long arm of Chromosome 4 (or D)  
 through linkage to the RFLP marker m506 (Chang et al., Proc  
 10 Natl Acad Sci USA (1988) 85: 6856-6860), in progeny of a cross  
 between *vrn2-1 fca-1* (*Ler* background) and *fca-10* (*Ws*  
 background). Further RFLP markers in this region (Liu et al.,  
 Plant J (1996) 10:733-736) were used to refine the position of  
 VRN2. We used standard RFLP techniques, using <sup>32</sup>P-labeled  
 15 cosmid probes, and a PhosphorImager detection system. A  
*Ler:Ws* RFLP was detected when using *EcoRI* digested genomic  
 DNA, and either g13683 or CC36F6 as probes. The g19247 marker  
 is a SSLP marker (using the primers g19247F and g19247R, see  
 below), with *Ler* producing a PCR-amplified band of  
 20 approximately 750 bp, while *Ws* produces a band of 862 bp.  
 Fine mapping of VRN2 was performed using a series of  
 PCR-derived markers, based on the Columbia genomic sequence in  
 this region (Bevan et al., *supra.*). The VRN2CD marker was  
 amplified with two primers, VRN2-C and VRN2-D, and digested  
 25 with *DdeI*. This produces a CAPS marker, with *Ler* producing  
 bands of (approximately) 480 bp, 290 bp and 190 bp, while *Ws*  
 produces bands of (approximately) 330 bp, 290 bp and 150 bp.  
 The VRN2RS marker is a dominant marker for *Ws* (i.e. *Ler:Ws*  
 heterozygotes cannot be distinguished from *Ws*), produced by

amplifying genomic DNA with VRN2-R and VRN2-S (see below), and digesting the product with *MboII*. This produces a single predominant band (and several much smaller unresolved bands) in Ler of approximately 400 bp, while Ws produces two bands, 400 bp and 300 bp.

#### Cosmid Isolation

Cosmids covering the region not covered by the subclones of EW16B10 YAC were identified through hybridization to BAC inserts derived from BACs T5015 and T1C7. BAC DNA was purified and the insert isolated following digestion with *NotI* and separation by pulsed field gel electrophoresis (PFGE) as described in (Bancroft et al., supra.). Purified BAC inserts were labeled with  $\alpha^{32}\text{P}$ -dCTP by random primed labeling, and hybridized to arrayed grids of a Ler genomic cosmid library. Positively hybridizing cosmids were identified, and rescreened following restriction enzyme digestion, southern blotting and hybridized to the BAC insert probe used initially. Cosmids in the region of interest were selected, and genomic sequence was obtained from the ends of the insert using the BIGDYE cycle sequencing kit, and T3 and T7 primers, whose sequences flank the genomic DNA insert site. This sequence was aligned with that of the Columbia genomic sequence to accurately position the cosmids.

#### Complementation

Cosmids in the 04541 binary vector were mobilized into *Agrobacterium tumefaciens* (strain C58C1 Rif<sup>R</sup> by tri-parental mating (Hoekema et al., Nature (1983) 303: 179-180). *vrn2-1*

*fca-1* plants were transformed with these *Agrobacterium* strains by vacuum infiltration (Bechtold et al, supra.). Transgenic T1 plants were selected on GM with Kanamycin (50 mg/mL), and transferred to soil when they had reached the 3-4 leaf stage.

5 The presence of each cosmid in the transgenic lines was confirmed using either a Ler/Col specific polymorphism (CAPS or SSLP marker) or more commonly, through the use of a specific diagnostic PCR reaction, using a primer present within the cosmid insert sequence and a primer present in the

10 cosmid flanking the insert site. Transgenic plants were also tested for the presence of the *fca-1* mutation, as the T0 plants should carry this mutation. Together, these two methods ensured that only *vrn2-1 fca-1* plants carrying the desired cosmids were analyzed further. We aimed to produced 5

15 to 6 independent T1 transformants for each cosmid, but for some cosmids only a single line was produced. However, as complementation was observed before we had generated T1s for all of the cosmids, we are continuing to produce additional transgenic T1 plants carrying the cosmids near VRN2. T1

20 plants were grown in a controlled environment chamber (conditions as above), and allowed to self. T2 seed were collected, and analyzed for the segregation of Kanamycin resistance or sensitivity on GM plates containing Kanamycin (as above), scored 14-20 days after germination. Progeny from

25 T1 plants that segregated a 3:1 ratio of resistant to sensitive plants were tested for their ability to complement the *vrn2-1* mutant phenotype, by vernalizing for 3 weeks and recording the total leaf number.



### Sequencing ORFs

Two potential open reading frames were sequenced following RT-PCR using RNA isolated from *fca-1* and *vrn2-1 fca-1* plants. cDNAs were reverse transcribed, primed by a dT12-18 primer, and specific primers were then used to PCR amplify regions corresponding to the ORFs for ATDL4450W and 5K (VRN2). The Boehringer Mannheim HiFi PCR system was used to increase the fidelity of amplification. The primers VRN2-AL and VRN2-AM were used to prime ATDL4450W, and VRN2-AI and VRN2-AJ for 5K. For 5K, the PCR reaction for the full length product (VRN2AI-VRN2AJ) was inefficient, so subsequent reactions were performed to amplify the cDNA in two overlapping fragments, using the primer combinations VRN2-AI with VRN2-AS; and VRN2-AO with VRN2-AJ. The PCR products were isolated and purified, and sequenced directly using the BIGDYE sequencing kit (PE Applied Biosystems). At least two independent PCR products were sequenced from each allele. We sequenced the ATDL4450W PCR products with the amplifying primers VRN2-AL, VRN2-AM, and VRN2-AU through VRN2-AX. The 5K cDNA was sequenced with VRN2-AI, VRN2-AJ and VRN2-AO through VRN2-AT. Sequences were aligned into contigs using the DNASTar software package (LaserGene).

### Sequence Comparisons

EST and cDNA sequences were first translated using the MapDraw program of DNASTar (LaserGene). This revealed several regions where the sequence appeared to be incorrect, as small changes to the described sequences drastically improved the similarity to VRN2. Modified nucleic and amino acid sequences were

initially aligned using programs within the MegAlign Package of DNASTar (LaserGene), as follows:

Amino acid sequences were initially aligned using the Clustal V method (Higgins and Sharp (1989) CABIOS vol. 5, no.2, 151-153). Default parameters were used: Gap penalty 10, Gap length penalty 10, ktuple 2, and the PAM 250 residue weight table. Alignment was refined by eye and hand, making minor adjustments to position of gaps to improve alignment.

10

Nucleic acid (EST and cDNA) sequences were initially aligned with the Hein method (Hein (1990) Methods in Enzymology, vol. 183, 626-645), using default parameters: Gap penalty 11, Gap length penalty 3, ktuple 2, and the weighted residue weight table. Where the nucleotide alignment (when translated) did not correspond to the amino acid alignment, the positions of gaps were adjusted to correspond with the gaps in the amino acid alignments.

#### 20 dCAPS Marker for the *vrn2-1* Mutation

A derived CAPS (dCAPS ) marker was designed that was specific for the *vrn2-1* mutation. Following PCR amplification from genomic DNA with the primers VRN2-AY and VRN2-AZ, the 170 bp product was digested overnight with XmnI restriction enzyme, and the products resolved on a 4% agarose gel. Wild type plants (VRN2) produce a single band of 170 bp following digestion, while *vrn2-1* mutants produce two bands, of 137 bp and 33 bp.

Primers Used to Identify VRN2

As indicated on Figure 3 and Figure 5. All primer sequences are indicated 5' to 3'.

5	g19247F	ACT GTT CGT CTC CTT CAT CAT G
	g19247R	TTG CTT GCC TGA AAA AAG TAT G
	VRN2-C	TGT CGA TAT GCG ACC AGT ACC
	VRN2-D	CAG GCT TAG ACC CAA TTG ACC
	VRN2-R	AGG TAG GAT CCG ACA TCG TCT TCT TAT TTA CCG
10	VRN2-S	CTC TTG AAT TCA AAA CTA TTC CTA CTC TCA CAC
	VRN2-AI	GCC AAT CGG TGT TTT CGC AGC TTT C
	VRN2-AJ	AAG AAT AAG TTA CAA TCC GAT AAA TCG G
	VRN2-AL	CAG TGG TTG AAG CTT AAG GAG G
	VRN2-AM	GCA ATG AAT AAA TCA TAA TCT TGG
15	VRN2-AO	TCT ACT GGG ATG GTA GTT TTC
	VRN2-AP	ATA TCC CGA GGC AAC AGA GCT TG
	VRN2-AQ	CAT CTT TGG AAC TCG TTT G
	VRN2-AR	CTC AGT TGT AAT AGT TGC CC
	VRN2-AS	AAG AGT GGG CTA TGG CTG G
20	VRN2-AT	GCA ACT CTT TCT CGT AAA ATC TTG
	VRN2-AU	GCC TCC ATA ACT GTC ATC ACA TC
	VRN2-AV	TTT CAT TGG TCA TGG GAT GG
	VRN2-AW	GAC TTC AGA GAT GGG TTT ATG C
	VRN2-AX	TCC ATA TCT AGC TCC TTC GCC
25	VRN2-AY	TGC GTT CAT TAA GTA GGC AAC AGA AAA TGG
	VRN2-AZ	GAG AAG TAG TTA CCT TTG TTT TCT TAC AGA AGA GT

Table 1 Comparison of VRN2 Nucleotide and Amino Acid Sequence to Database Sequences

Sequence	Nucleotides			Amino Acids		
	Identity (%)	Length	Range <sup>a</sup>	Identity (%)	Similarity (%) <sup>b</sup>	Range <sup>c</sup>
VRN2 Col	96.5	1722	1-1722	96.1	96.8	1-445
C72616 Region I	32.4	219	681-899	15.1	42.5	73
C72616 Region II	71.7	247	951-1197	72.7	85.7	82
C72616 Complete	47.7	517	681-1197	40.1	58.1	172
At163743 Region I	41.0	61	839-899	27.3	68.1	22
At163743 Region II	71.6	264	951-1214	66.7	77.1	88
At163743 Complete	65.8	376	839-1214	52.8	66.6	127
AtHyp 2245035	66.3	570	924-1493	63.7	79.5	190
KIAA0160 Region I	36.6	396	231-626	20.4	39.4	132
KIAA0160 Region II	35.5	904	819-1722	17.7	43.4	249
KIAA0160 Complete	41.1	1492	231-1722	16.0	36.0	445

a Numbered relative to VRN2 cDNA sequence

b Similarity defined as identity plus similarity on the basis of amino acids grouped into four classes - (D, E), (R, K, H), (S, T, N, Q, Y), and (L, I, V, M, A, G, W, F, P, C)

c Numbered relative to VRN2 amino acid sequence

Table 2 Putative Domains of the VRN2 Protein

"Domain"	"Sub-domain"	Length	Position <sup>a</sup>	Identity (%)	Similarity (%) <sup>b</sup>	Molecule
DNA/Protein-Binding		70	63-132	30.0	51.4	KIAA0160
	Zinc Finger Motif	22	90-111	50.0	68.1	Mm Spalt 1296845
		22	90-111	45.4	68.1	Sc TFIIIA 730931
		22	90-111	40.1	72.7	Ce Hyp 2854197
		22	90-111	36.4	50.0	KIAA0160
Activation	Conserved Region	41	76-116	43.9	61.0	KIAA0160
		66	263-328	89.4	95.4	At163743
		68	263-330	83.0	93.2	C72616
		104	263-366	58.6	76.0	At Hyp 2245035
		104	263-366	29.8	49.0	KIAA0160
Conserved Acidic Region		36	281-316	94.4	97.2	At163743
		36	281-316	86.1	94.4	C72616
		36	281-316	58.3	72.2	At Hyp 2254035
		36	281-316	30.5	50.0	KIAA0160

a Position relative to VRN2 Amino Acid sequence

b Similarity was calculated as defined in Table 1

SEQ ID NO: 1

CAAGCTTCTTCAATTTTGCTTGCTCTCTCTTACACAGCCAATCGGTGTTTTCGCAGCTTTCA  
GGCCTCAATCCAAGACATTCTATATAAGCATATTGCAGAAGAGGCGGTCTAATTGTTGCAT  
5 TGAGTTTATCGCTATGACGTAGGGAAATTCTAATTTAGGGGAGGCCTCAGAGTTTGCCTAA  
CTTCATAATCGGCTCTTGACGTTGTTGAGTGAATTGAACAAGAATGTGTAGGCAGAATTGT  
CGCGCGAAATCCTCACCGGAGGAAGTGATTTCAACTGATGAGAATCTCTTGATATATTGTAA  
ACCTGTTGACTATATAACATCTTTCACCTTCGCTCTCTAGGCAACCCATCGTTTCTTCCAA  
GATGCTTGAAGTACAAAATTGGAGCAAAGCGCAAAGAAAGTCAAGATCTACTGGGATGGTA  
10 GTTTTCAACTATAAGGATTGTAATAACACATTACAGAAACTGAAGTTAGGGAGGATTGTTT  
TTGTCCATTTTGCTCTATGCTATGTGGTAGCTTCAAGGGGCTGCAATTTCAATTTGAATTCAT  
CTCATGATTTATTTGAATTTGAGTTCAAGCTTTTGAAGAATACCAGACAGTTAATGTTTCT  
GTAAACTTAATTCCTTCATATTTGAGGAAGAAGGAAGTGATGACGATAAATTTGAGCCCTT  
CTCTCTCTGCTCGAAACCTCGTAAGCGGAGACAAAGAGGTGGCAGAAATAACACCAGGAGAC  
15 TTAAAGTATGCTTTTTTACCGTTGGATTCACCCAGTTTAACTAATGGCACAGAAAATGGAATC  
ACCCTACTTAATGATGGAAACCGTGGTTTAGGATATCCCGAGGCAACAGAGCTTGCTGGACA  
ATTTGAGATGACCAGCAACATTCACCAGCCATAGCCCACTCTTCTCTGGACGCTGGTGCTA  
AAGTTATATTGACAAGCGAAGCTGTGGTCCCTGCTACTAAGACAAGAAAGTTATCTGCTGAG  
CGATCAGAGGCTAGAAGCCACCTACTTCTTCAGAAACGCCAATTCTATCATTCTCACAGAGT  
20 CCAGCCAATGGCGCTTGAGCAAGTAATGTCTGACCGGGATAGCGAGGATGAAGTCGATGACG  
ATGTTGCAGATTTTGAAGATCGCCAGATGCTTGATGACTTTGTGGATGTGAATAAAGATGAA  
AAGCAATTCATGCATCTTTGGAAGTCGTTTGTAAAGAAAACAAAGGGTTATAGCAGATGGTCA  
TATCTCTTGGGCATGTGAAGCATTTTCAAGATTTTACGAGAAAGAGTTGCACCGTTACTCAT  
CACTCTTCTGGTGTGAGATTGTTTTTGATTAACTATGGAACCATGGACTTGTGACTCA  
25 GCCACCATCAACAACTGCAATACCATCCTCGAGAATTGCCGTAATAGCTCAGACACCACCAC  
CACCAACAACAACAAGTGTGGATCGTCCCAGTGAAGTCAAACACCAACAACAATAACATTG  
TGGATCATCCCAATGACATAAACAACAAGAACAATGTTGACAACAAGGACAATAACAGCAGA  
GACAAAGTAATTAAATAGGAAAATCTCCGGCTTTTATGATACCGATTTATCGGATTGTAAGT  
TATTCTTCTTTCTTAAAAAATTGTTTAGGAGCAAACAATTTTTTATATGTTAGTGATTCA

ACTGATTACATTTTTAGTTAAAAAAAATGGATTCTGCTTATAACT

SEQ ID NO: 2

5

MCRQNCRAKSSPEEVI STDENLLIYCKPVRLYNIFHLRSLGNPSFLPRCLNYKIGAKRKRKS  
RSTGMVVFNYKDCNNTLQKTEVREDCSCPFC SMLCGSFKGLQFHLNSSHDLFEFEFKLFEEY  
QTVNVSVKLNSFIFEEEGSDDDKFEPFSLCSKPRKRRQRGGRNNTRRLKVCFLPLDSPSLTN  
GTENGITLLNDGNRGLGYPEATELAGQFEMTSNIPPAIAHSSLDAGAKVILTSEAVVPATKT  
10 RKLSEARSEARSHLLLQKRQFYHSHRVQPMALEQVMSDRDSEDEVDDDVADFEDRQMLDDFV  
DVNKDEKQFMHLWNSFVRKQRVIA DGHISWACEAFSRFYEKELHRYSSLFWCWRLFLIKLWN  
HGLVDSATINNCNTILENCRNSSDTTTTNNNNNSVDRPSDSNTNNNNIVDHPNDINNKNVNDN  
KDNNSRDKVIK

15

SEQ ID NO: 3

20

25

AAAGAGAATGCTTTGACTCTCTCATTGGTCAAACCTGACTGTATTTATATGCGTTATTGTGT  
GGTAAAGTTTCGACCTTTGACTTTACAAGTTGGCGTTAAGAAGAGAGATGCGTAGATCAGCG  
20 AGTGGTTCGAGAGTTTTGGATCATTTTCCCCGACTTCACGGTCTCCACGTCGATCTCAGAG  
CATTACATCATTGGAAGATGATGTGGAGGTGCTTTTGCCTAGGTACGATCCGAATTCTCAAG  
CGGGGAAGAGAGAGAAGTCAAGATTCAGATTTCAGAAAACGTCATCCATTTGATTCCTCTC  
ATTCTTCTTCTCTGTATCGCAATCCTCTGGCTCTCCTCTTATTCAGGTAAGCCGAGAAATTG  
ATTCAATCTCTATGAATCCATAATTGATATGTGAAACTTAATTAGGGATTTTACAAAGGCTC  
25 ATATGGATATGATATGAGGATCGAGATGTCTCTGTAACATTAGAATCTTGTGTTGAATTATT  
GTTTCAATTTGTTTCATATTATACTAAACCGGTGATGGATTTGGAATTTGTCAGCAGCGTTAA  
GGAGTTGAGTTCAAGAAGCAACATGTTGTCTTGTCTCCATGGGAACATCATATTCAGTTT  
TGGGAAAGGAAACAATTTTTTTTACCGCCGGTGATTATGTGCCGCAAACCATACGTAACTTT  
TGTAATTTTCGGTTCTGTAGACACATAAAAGGATCTCTCGTTTTTCATGAAATGTATGTTTAA

TATTTCACTATACATCACACAACCTCAAGTAGAAAACACTGATGGTTATCCATTAATCATCAT  
TCTATTGGTCGAAAACAAGGATTAGTTTCAACTTATTGCTACCTTAGTGATTAGATGTTTCCT  
GTGAGTTTCAGCTAGCCAAGTCAACTAGAGTTAAACAATGGAATCAAAATACATATTCAGTA  
ATTTATTTTAAACTCTGACTATTTATGTAAACAAAAATGGAAATTAAAATTGAAGGTCATGA  
5 AGATTCTATTCTTAGTATGAAAAGTATAGATCAATGATAAAAGTATATACCAGAACAGTGGT  
GGATCTAGAAACATATTTAGTATATGGCACAATATATTTAACATATACAAATTTTAATCTAA  
AAGTTGTATTCAATTTATGAAAAGACWTCTGAATGAAGCAAATTTATTTGATGTGTTAATCAT  
CCATTTATGTGTTAATCAGCCATTGATGTTAGTATAGTACTCTATGCTAACATAATTTTTTT  
ATACTATAAATTAAAAAAATAGGTAAGAAAAGAAAAATAGATTAATATAAAAAGCATTTTAT  
10 TAGCTGAAATAAATAAAATGAAAGAAGATAATAACTAATTGACTAAAAAATTAGTAGAGCAT  
ATGGGGCACAATACACTAAGTATTTTCATCTTTACTATAAAATGTAACAAATTTCAAATTAT  
CAAAGTGTATATAGGGCACGTGCCTAGGTACCAATAGACGTACGTCCGCCCTGAAATAAGTT  
GGTGAATATGGTTTTAATTCCTCTAATACTCACTGTACTGCCATGGTAGAGGTGAAAAAAC  
AATTTTAGAAATATTATAATGGATTAAGCTGTCCAAGTTGGTCGTATTTTCTTTACATTTTA  
15 TTAACATAAATAAATAAATAAGTTCAACTATTTATTGACTAGTAATAATACGTGTAAATGT  
CTATTGGTTTTAAATATGGGCCATAAGGCCAGACTTGAAAAAAAACCTGAAACCCAAAGT  
TATATTTTTACTTGTTTCTTCTTCTCAGTGAATATCTCCAATCAAGCTTCTTCGATTTTG  
CTCTCTCTTACACAGCCAATCGGTGTTTTTCGCAGCTTTCAGGTTTGCTCAATCTCAAATTA  
AATCGGAGTCAAGTAATAACAATTGATAAACCTAATTGTTTCCATTGTATTGTAAGATTGA  
20 AATTTTGCTGTAGATCCGGAATCGAATTCTAGTTCTGGAATCGTTGATCTCGATGGAATTTT  
TTTTTTAAGATTTCTTCTTACACATTTGGTTCAAAGATCACATAGTTTATTTTAATTTGA  
TAAGTATGATGATTCTGCTAAGTGGCATTGGATAAAGTTTTCGTTTTTGCAATACGTCTAAA  
CTTGTCTATGTCTTGAATGAACTCTCTGAGTTGCTTAAAAAGTCTTGTGCTTTCTTTATTAC  
ACAGGCCTCAATCCAAGACATTCTATATAAGCATATTGCAGAAGAGGCGGTTCTAATTGTTG  
25 CATTGAGTTTATCGCTATGACGTAGGGAAATTCTAATTTAGGGGAGGCCTCAGAGTTTGCAC  
TAACTTCATAATCGGCTCTTGACGTTGTTGAGTGAATTGAACAAGAATGTGTAGGCAGAAT  
TGTCGCGCGAAATCCTCACCGGAGGAAGTGATTTCAACTGATGAGAATCTCTTGATATATTG  
TAAACCTGTTGACTATATAACATCTTTCACCTTCGCTCTCTAGGCAACGTATGATTTGCCT  
TCCTCTCTCATCATATTAGCTCAGTAATCTTTCATCTCCTGTGTAGATCACCCACTAATAGT



TTGAGTTTGCTAAGCTGATTATGGTCTGATTCATGGCGAGTGTGTGCTTCTTTTGTCTCCTA  
AATTTGAACTTGTTGTTTGTGTTGTCAGCCATCGTTTCTTCCAAGATGCTTGAACACAAAA  
TTGGAGCAAAGCGCAAAAGAAAGTATGTTTTCTTCTTGAATGTAGCTGCTACAGTGATATGT  
TATTTATCTTACTTCTAATATGGAAGCTGATGACCTATTTTATCTTTGTTGAGTAGATATGG  
5 ACATAATGAATGGTTTCTTCTTTGTTCATGCTATAAACTTACATTTTATAAAATTGTGTTTT  
GGTTAGGTCAAGATCTACTGGGATGGTAGTTTTCAACTATAAGGATTGTAATAACACATTAC  
AGAAAACCTGAAGGTTAGTCTTTTTCTGTTCGTCGACAAAATTTCGATGTCAATGTCTATGTTT  
CTCTAGATGATTTGTTATTTACTATTTTTTTCTGTATTGTCATGCAGTTAGGGAGGATTGTT  
CTTGTCATTTTGTCTCTATGCTATGTGGTAGCTTCAAGGTGGGCAACTATTACAACCTGAGGT  
10 TTCTTCCGGGGCCTTTCATATCTAACACTGTGAAATGCTACTGCTGTTTCATGCTGTATACT  
TTCCTGTTTGGTTACATATTTTTGTGTTTGTGTTTGTCTTCTCACTCTTTTCGAACTGCT  
GAGTGTGTGCTTATCTGAGAAAACATGTCCCAGATGGAGCTTACAACCAATTGTCTTGTGTC  
TATGCAGGGGCTGCAATTTCAATTTGAATTCATCTCATGATTTATTTGAATTTGAGTTCAAGG  
TATGTGGTTTTATGGAAATTCTTGATTTGCTATGCCTTTATTAATGAGGTTATAGTTAAAAA  
15 AGGGTCTTTCCTATTGTAGCTTTCGGAAGAATACCAGACAGTTAATGTTTCTGTAAAACTTA  
ATTCCTTCATATTTGAGGTCAGTTACTTTAAACTTGGTTAATTGGGAAATCCGATAGCTGGT  
GAAAATTTTGTTTATATTCCATCCTTATTTGTACTAGGAAGAAGGAAGTGATGACGATAAAT  
TTGAGCCCTTCTCTCTCTGGTAACCCCTCAGAACCCCTTCGATTAAATACCTTAATAGCAGTA  
ACTCCTTGCTTCTCTTGTGTCAGTACATCTCTGTAAATCCAACCATAATGTTTTGCAGCTCGAA  
20 ACCTCGTAAGCGGAGACAAAGAGGTGGCAGAAATAACACCAGGAGACTTAAAGTATGCTTTT  
TACCGTTGGATTACCCAGTTTAACTAATGGCACAGAAAATGGAATCACCTACTTAATGAT  
GGTAAAATCATATCTTCTTCTGTGCGTTCCTTGTGGCTTAGAACTTCATATTACAGAAGAAG  
ATACAATGGCCTGATTGTTTAGTTTTGTACTTCTCCTCGCATTCTTCTTGCGAGGGTATTG  
TTACCAGAACTGATGTACAAAATTAATGGCATGCTACAGGAAACCGTGGTTTAGGATATCCC  
25 GAGGCAACAGARCTTGCTGGACAATTTGAGATGACCAGCAACATTCCACCAGCCATAGCCCA  
CTCTTCTCTGGACGCTGGTGCTAAAGTTATATTGACAAGCGAAGCTGTGGTCCCTGCTACTA  
AGACAAGAAAGTTATCTGCTGAGCGATCAGAGGCTAGAAGGTTTGTTCATCATGACACCCCG  
TCATCATAATTACCATTCTGTTGTTACAAATGTTCTTCTTCTATTATGGATAAGTGTTTATAG  
TACTGCCATATTAACCGAGAAAATTTCTTCCAGCCACCTACTTCTTCAGAAACGCCAATTCT

ATCATTCTCACAGAGTCCAGGTGATCCAAGTTCCTTCACCTACTTCTTAGGCATTTTCTTTA  
AATTGCTCATGATGATATCTTATCAAAGCATACTTGGTTTGTTCATCCAAATTTGTATTT  
TGATCTGTATGTATCAACGCAAAATAGTTATGTCCATGTTGTCTCCGTTTTATTGCCACTAA  
CCAAAAATGCATGTTTCTGTGACAAGCCAATGGCGCTTGAGCAAGTAATGTCTGACCGGGA  
5 TAGCGAGGATGAAGTCGATGACGATGTTGCAGATTTTGAAGATCGCCAGGTATTCCATGATT  
TCTTTCTGCGTTCATTAAATAGACAACAGAAAATGGTATATGATGTAACCTTGCTAATGGCTT  
TTGAAACTTAAAAAGCTGCAGATGCTTGATGACTTTGTGGATGTGAATAAAGATGAAAAGC  
AATTCATGCATCTTTGGAACCTCGTTTGTAGAAAACAAAGGTAACCTACTTCTCTTACACATG  
AACAGACACAAAAAGACCTTATGTCTTACATTCCATACCTGTCTAAATGATTTTGCTTATGG  
10 AACTTTGAGCTCAATTATGATTGTTGATGTTTCAGGGTTATAGCAGATGGTCATATTTCTTG  
GGCATGTGAAGCATTTTCAAGATTTTACGAGAAAGAGTTGCACCGTTACTCATCACTCTTCT  
GGTAATATAAGTACACCAAACATATACAGACACATAACTACACTATCAATCTTGTTTCGTTT  
TCTGAAAAAAAATAAAAATTTCCAGGTGTTGGAGATTGTTTTTGTATTAAACTATGGAACCA  
TGGACTTGTGCTGACTCAGCCACCATCAACAACCTGCAATACCATCCTCGAGAATTGCCGTAATA  
15 GCTCAGACACCACCACCACCAACAACAACAGTGTGGATCGTCCCAGTGACTCAAACACC  
AACAACAATAACATTGTGGRTCATCCCAATGACATAAACAACAAGAACAATGTTGACAACAA  
GGACAATAACAGCAGAGACAAAGTAATTAAATAGGAAAATCTCCGGCTTTTATGATACCGAT  
TTATCGGATTGTAACCTATTCTTCTTTCTTAAAAAATTGTTTAGGAGCAAACAAATTTTTTA  
TATGTTAGTGTATTCAACTGATTACATTTTTAGTTAAAAAATAATGGATTCTGCTTATAA  
20 CTAAAACTGAAAAAAAGAAAAGTTTCCTTAATTTTTCTTTTTGACTTGAGAAAAGCTCC  
TCTAGTAAATATGAGTTATATATTAATCAAGTACATAACATAAAAATAGTATATATTAAGTG  
CAAATAGATTGAAAACAAATCAAGAAGAAATTAATTAAGACAGAGTGATTAAGCTTAAAACC  
CCATTTGGACTTGTTCTTTCTCAATGAATCCCTCACAAGCAGCAAGCTTCTTCGATTTTGCT  
TTGACACCACCAATCGGTGTTTTCGAATCTTTCAGGTTTGTCTCGATTTCATCTAGATCGG  
25 AGTCAAGTAATAAAATTGATTAACCTAAGTATTCCTCGTAAGAGTTGGGATTTAG  
CAGTAGATCGGAAATCGGAATTTACGTTTTGTAAAGATTGATGGTTTAGGTAATGGAAC  
ATAGTTCTGGATTCATTGCTTCTAGTTGATTCTCGAATTGTTTGATTTCGCAATGCACATTT  
TTGTTTCAAAGGATCACAGAATTTGATTTAAAATTTGACAAAATTCCATCAATTTCTCATAT  
TAGGGTTTATATTTCTTCTAGTAACTCGAACTTGTTGGAACCTCTGTATACTCTGTGCTATGT

AGATAAAGTCTTAACATTTTGGTCAACTTTGTTTGATCTCTAACTAGTTTGGGCTCTCTGT  
TTTAAAGTTTTGTGCTTTCACTATTACACAGGTCTCATAACAAGACTACAGTCTCAAGAAGCA  
TAATATCGTCGACTCTGTTTTGAGTTTCTCAACAGTGGTTGAAGCTTAAGGAGGTTCTTATG  
TGCGTTTTGATATC

5

SEQ ID NO: 4

CAAGCTTCTTCAATTTTGCTTGCTCTCTCTCTTACACGGCCAATCGGTGTTTTTCGCAGCTTT  
10 CAGGCCTCAATACAAGACATTCTATATAAGCATATTGCAGAAGAGGCGGTTCTAATTGTTGC  
ATGGAGTTGAACAATATGACGTAGGGAAATTCTAATTTAGGGGAGGCCTCAGAGTTTGCACT  
AACTTCATAATCAGCTCTGGACGTTGTTGATTGTATTTGAACAAGAATGTGTAGGCAGAATT  
GTCGCGCGAAATCCTCACCGGAGGAAGTGATTTCAACTGATGAGAATCTCTTGATATATTGT  
AAACCTGTTCGACTATATAACATCTTTCACCTTCGCTCTCTAGGCAACCCATCGTTTTCTGCC  
15 AAGATGCTTGAAC TACAAAATTGGGGCAAAGCGCAAAGAAAGTCAAGATCTACTGGGATGG  
TAGTTTTCAACTATAAGGATTGTAATAATACATTACAAAGAACTGAAGTTAGGGAGGATTGT  
TCTTGTCCATTTTGCTCTATGCTATGTGGTAGCTTCAAGGGGCTGCAATTTCAATTTGAATTC  
ATCTCATGATTTATTTGAATTTGAGTTCAAGCTTTTGGAAGAATACCAGACAGTTAATGTTT  
CTGTAAAACTTAATTCCTTCATATTTGAGGAAGAAGGAAGTGATGATGATAAATTTGAGCCC  
20 TTCTCTCTCTGCTCGAAACCTCGTAAGCGTAGACAAAGAGGTGGCAGAAATAACACCAGGAG  
ACTTAAAGTATGCTTTTTTACCGTTGGATTACCCAGTTTAGCTAATGGCACAGAAAATGGAA  
TTGCCCTGCTGAATGATGGAAACCGTGGTTTAGGATATCCCGAGGCAACAGAGCTTGCTGGA  
CAATTTGAGATGACTAGCAACATTCCACCAGCCATAGCCCCTCTCTCTGGACGCTGGTGC  
TAAAGTTATATTAACAACCGAAGCTGTGGTCCCTGCTACTAAGACAAGAAAGTTATCTGCTG  
25 AGCGATCAGAGGCTAGAAGCCACCTACTTCTTCAGAAACGCCAATTCTATCATTCTCACAGA  
GTCCAGCCAATGGCGCTTGAGCAAGTAATGTCTGATCGGGATAGCGAGGATGAAGTCGATGA  
CGATGTTGCAGATTTTGAAGATCGCCAGATGCTTGATGACTTTGTGGATGTGAATAAAGATG  
AAAAGCAATTCATGCATCTTTGGAAC TCGTTTGTAAGAAAACAAAGGGTTATAGCAGATGGT  
CATATCTCTTGGGCATGTGAAGTATTTTCAAGATTTTACGAGAAAGAGTTGCACTGTTACTC

ATCACTCTTCTGGTGTGGAGATTGTTTTTGATTAAACTATGGAACCATGGACTTGTGCGACT  
CAGCCACCATCAACAACACTGCAATACCATCCTCGAGAATTGCCGTAATACCTCAGTCACTAAC  
AACAACAACAACAGTGTGGATCATCCCAGTGACTCAAACACCAACAACAATAACATTGTGGA  
TCATCCGAATGACATAAAAAACAAGAACAATGTTGACAACAAGGACAATAACAGCAGAGACA  
5 AGTAATTAAATAGGAAACACTCCGGTTTAGATGATACCGATCTATCGGATTGTAACCTTATTC  
TTCTTTCTTAAAAAATTGTTTAGGAGCAAACAAAGATTTTATTTGTTAGTGTATTCAACTG  
ATTACATTTTTAGTTAAAAAATGGATTCTCCTTAATAACT

10 SEQ ID NO: 5

MCRQNCRAKSSPEEVISTDENLLIYCKPVRLYNIFHLRSLGNPSFLPRCLNYKIGAKRKRKS  
RSTGMVVFNYKDCNNTLQRTEVREDCSCPFCSMLCGSFKGLQFHLNSSHDLFEFEFKLLEEY  
QTVNVSVKLNSFIFEEEGSDDDKFEPFSLCSKPRKRRQRGGRNNTRLKVCFLPLDSPSLAN  
15 GTENGIALLDGNGRGLGYPEATELAGQFEMTSNIPPAIAHSSLDAGAKVILTTEAVVPATKT  
RKLSEARSEARSHLLLQKRQFYHSHRVQPMALEQVMSDRDSEDEVDDDVADFEDRQMLDDFV  
DVNKDEKQFMHLWNSFVRKQRVADGHISWACEVFSRFYEKELHCYSSLFWCWRLFLIKLWN  
HGLVDSATINNCNTILENCRNTSVTNNNNNSVDHPSDSNTNNNNIVDHPNDIKNKNNVDNKD  
NNSRDK

20

SEQ ID NO: 6

AAAGAGAAGAGCTTTGACTCTCTCATTGGTCAAACCTGACTGTATTTATATGCGTTATTGTG  
25 TGGTAAAGTTTCGACCTTTGACTTGACAAGTTGCCGTTAAGAAGAGAGATGCGTAGATCAGC  
GAGTGGTTCTAGAGTTTTGGATCATTTTCCGGCGACTTCAAGGTCTCCGCCTCGATCTCAGA  
GTGTTACAGCAATGGAAGATGATGTGGAGCTGCTTTTGCCTAGGTACGATCCGAATTCTCAA  
CGGGGAAGAGAGAGAAATCAAGATTCAGATTTTCAGAAAACGTCATCCATTTGATTCCTCT  
CATCTTTCTTCTCTGTGTCGCAATCCTCTGGCTCTCCTCTTACTCAGGTAAGCCGAGAAATT

GTTTCAATCTCTATGAATCCATAATTGATCTGTGAACTTAATTAGGGATTTTACAAAGACT  
CATATGGATATGAGGATCGAGATGTCTCTGCAACGTTAGAATCTTGTGTTGAATTATGGTTT  
CAATTTGTTTCATATAATACTAAATCGGTGATGGATTTGGAATTTGTCAGCAGCGTTAAGGAG  
TTGAGTTCCAAAAGCAACATGTTGTCTTGTCTCCATGGGAACATATTCAGTTTTGGGAAA  
5 GGAAACAATTCTTTTACCGCCGGTGATTTTGTGCCGCAAACCATTCGTATTTGTAATTTTGTG  
GTTCTGTAGACACACAAAAGGATCTCTCGTTTTTCATGAAATGTATGTTTAATATTTTCAGTGA  
TATACATCACACAACCTCAAGTAGAAAACACTGATGGTTATCCATTAATCATTCTATTGGTCG  
AAAAAAGATTAGTTTCAACTTAATGCCACCTTAGGATTATATGTTCCCTGTGAGTTTCAGCT  
AGCCAACTCAACTAGAGTTAAACAATGGAATCAAAATACATATTCAGTAATTTATTTTAAAC  
10 TCTGACTATTTATGTAAACACAAATGGAAATCAAAATTGAAGGTCATGAAGATTCTATTCT  
TAGTGTGAAAAGTATAGATCAATGATTCTTAATTTCTTCATCCTCCACGCATAGATCAATGG  
TGAATATGGTTTTAAATCCTCTAATACTCACTGTACTGCCATGGTAGAGTTAAAAAACAAT  
TTTAGAAATATTAGTGGATTAAGGCATTAAGCTGTCCAAGTTGCTTGTATTTTCTTTTCATT  
TTATTAATTAAAAAAAAGTTCAACTATTTATTGACTAATAATAATACGTGTAAATGGTTA  
15 TCGGTTTTAAATATGGGCCATAGGCCCAGACTTGAAGAAAACTTGAAACCCAAAGTTTTAT  
TTTTACTTGTTTTCTTTCTCAGTGAATATCTCCCAATCAAGCTTCTTCAATTTTGCTTGCTC  
TCTCTCTTACACGGCCAATCGGTGTTTTCGCAGCTTTCAGGTTTGTCTCAATCTCAAATTAA  
ATCGGAGTCAAGTAATAACAATTGATAACCCTAATTGTTTCAATTATATTGTAAGATTTGAA  
ATTTTGCAGTAGATCCGGAATCGTATTCTAGTTCTGGAATCGTTGATCTCGATGGAATTTTT  
20 TTTAAGATTTCTTCATACACATTTGGTTCAAAGATCACATAATTTTATTTTAATTTGATAA  
GTATGATGATTCTGCTAAGTGGCATTGGATAAAGTTTTCATTTTTGCAATACGTCTAACTT  
GTCTATGTCTTGAATGAACTCTCTGAGTTGCTTAAAAAGTCTTGTGCTTTCTTTATTACACA  
GGCCTCAATACAAGACATTCTATATAAGCATATTGCAGAAGAGGCGGTTCTAATTGTTGCAT  
GGAGTTGAACAATATGACGTAGGGAAATTCTAATTTAGGGGAGGCCTCAGAGTTTGCCTAA  
25 CTTCATAATCAGCTCTGGACGTTGTTGATTGTATTTGAACAAGAATGTGTAGGCAGAATTGT  
CGCGCGAAATCCTCACC GGAGGAAGTGATTTCAACTGATGAGAATCTCTTGATATATTGTAA  
ACCTGTTTCGACTATATAACATCTTTCACCTTCGCTCTCTAGGCAACGTATGATTTGGCCTTC  
CTCTCTCATCATTTTAGCTTAGTAATCTTTCATCTCCTGTGTAGATCACCCACTAATAGTTT  
GAGTTTGCTAAGCTGATTATGGTCTGACTCATGGCGAGTGTGTGCTTCTTTTGTCTCCTAAT

GTTATTTGAACTTGTTGTTTGTGTTGTCAGCCATCGTTTCTGCCAAGATGCTTGAAC TACAA  
AATTGGGGCAAAGCGCAAAGAAAGTATGCGTTTCTTCTTGAATGTAGTTGCCACAGTGATA  
TGTTATTTATCTTACTTCTAATATGGAAGCTGATGAACTATTTATCTTTGTTGAGTAGATAT  
GGACATAATGAATGGTTTCTTCTTTGTTTCATGCTATACACTTATATTTTACAAAATTGTGTT  
5 TTGCTTAGGTCAAGATCTACTGGGATGGTAGTTTTCAACTATAAGGATTGTAATAATACATT  
ACAAAGAACTGAAGGTTAGTCTTTTTCTGTTCTTCGACAAAATTCGATGTCAATGTCTATGT  
TTCTCTAGATGATTTGTTATTTACTATTTTTTCTGTATTGTCACGCAGTTAGGGAGGATTG  
TTCTTGTCATTTTGTCTCTATGCTATGTGGTAGCTTCAAGGTGGGCAACTATTACAAGTGA  
GTTTCTTCCGGGGCCTTTCATATCTAACACTGTGAAATGCTACTGCCGTTAATGCTATATA  
10 CTTTCACTGTTTGGTTACATATTTTGTGTTTGTGTTTGTCTTCTTGCTCTTTTAAACTG  
CTGAGTGTGTGCTTATCTGAGAAAACATGTTCCAGTTCGAGCTTACAATCCATTGTCTGTG  
TCTATGCAGGGGCTGCAATTTCAATTTGAATTCATCTCATGATTTATTTGAATTTGAGTTCAA  
GGTATGTGGTTTTATGGAATTTCTTGTTTTGCCTATGCCGTTAGTAATGAGGTTATAGTTAA  
AAAAGGGTCTTTCCTATTGTAGCTTTTGAAGAATACCAGACAGTTAATGTTTCTGTAAAC  
15 TTAATTCCTTCATATTTGAGGTCAGTTACTTTAAACTTGGTTAATTGGGAAATCCTATAGCT  
GGTGAAAATTTGGTTTATATTCCATCCTTATTTGTACTAGGAAGAAGGAAGTGATGATGATA  
AATTTGAGCCCTTCTCTCTCTGGTAACTCTCAGAACCCCTTGATTAAATACCTTAATAGCAG  
TAACTCCTTGCTTTTCTTGTCAGTACTTCTCTATAAATCCAACCACAATGTTTTGCAGCTCG  
AAACCTCGTAAGCGTAGACAAAGAGGTGGCAGAAATAACACCAGGAGACTTAAAGTATGCTT  
20 TTTACCGTTGGATTACCCAGTTTAGCTAATGGCACAGAAAATGGAATTGCCCTGCTGAATG  
ATGGTAAAATCACATCTTCTTCTGTGGTATTCGTTGTGGCTTAGAACTTCATTTACAGAAG  
AAGATACAATGTCCTGATTGTTTAGTTTTGTACTTCTCCTCGCATTCTTCTTGAGGGTA  
ATGTTACCAGAACTGATGTACAAAATTAATGGCATGCTACAGGAAACCGTGGTTTAGGATAT  
CCCGAGGCAACAGAGCTTGCTGGACAATTTGAGATGACTAGCAACATTCCACCAGCCATAGC  
25 CCACTCTTCTCTGGACGCTGGTGCTAAAGTTATATTAACAACCGAAGCTGTGGTCCCTGCTA  
CTAAGACAAGAAAGTTATCTGCTGAGCGATCAGAGGCTAGAAGGTTTGTTCATCATGACACC  
CCGTCATCATAATTACCATACCTGTTGTTACAAATGTTCTTCCTATTATGGATAAGTGTTTA  
CTGTACTGCCATATTAACCGAGAAAATTTCTTCCAGCCACCTACTTCTTCAGAAACGCCAAT  
TCTATCATTCTCACAGAGTCCAGGTGATCCAAGTTCCTTCACCTACTTCTTAGGCATTTTCT

TTAAATTGCTCATGATGATATCTTATCAAAGCATACTTGGTTTGTCTCATCTAAATTTGTA  
TTTTGATTCTGTATGTATCAACGCAAAAAAATTATGTCCATGTTGTCTCCGTTTTATTGCCA  
CTAACCAAAACTGCATGTTTCTTGTGACAAGCCAATGGCGCTTGAGCAAGTAATGTCTGAT  
CGGGATAGCGAGGATGAAGTCGATGACGATGTTGCAGATTTTGAAGATCGCCAGGTATTCCA  
5 TGATTTCTTTCTGCGTTCATTAAGTAGGCAACAGAAAATGGTATACGATGTAAGTTGCTAAT  
GGCTTTTGAACTTAAAAAAGCTGCAGATGCTTGATGACTTTGTGGATGTGAATAAAGATGA  
AAAGCAATTCATGCATCTTTGGAAGTCGTTTGTAAGAAAACAAAGGTAAGTACTTCTCTTAC  
ACTTGAACACACACAAAAAGACCTTATGTCTTACATTCCATACCTGTCTAAATGATTCTGCT  
TATGGAAGTTTGAGCTCAAATTATGATTGATGTTTGCAGGGTTATAGCAGATGGTCATATCT  
10 CTTGGGCATGTGAAGTATTTTCAAGATTTTACGAGAAAGAGTTGCACTGTTACTCATCACTC  
TTCTGGTAATATAAGTACACCAAACATATACAGACACATAACTACACTATCAATTTTGTTTC  
GTTTTTCTGAAAGAAAAATAAAAAATTCCAGGTGTTGGAGATTGTTTTTGATTAACTATGG  
AACCATGGACTTGTGACTCAGCCACCATCAACAAGTCAATACCATCCTCGAGAATTGCCG  
TAATACCTCAGTCACTAACAACAACAACAGTGTGGATCATCCCAGTGACTCAAACACCA  
15 ACAACAATAACATTGTGGATCATCCGAATGACATAAAAAACAAGAACAATGTTGACAACAAG  
GACAATAACAGCAGAGACAAGTAATTAAATAGGAAACACTCCGGTTTAGATGATACCGATCT  
ATCGGATTGTAAGTTATTCTTCTTTCTTAAAAAATTGTTTAGGAGCAAACAAAGATTTTAT  
TTGTTAGTGTATTCAACTGATTACATTTTTAGTTAAAAAATGGATTCTCCTTAATAACTAA  
AGACTGAAAAATAAGATAAGTTTCCTTAATTTTTCTTTTTGACTTGAGAAAAAGCTCCTCTA  
20 GACCTCTAGTAAATAGGAGTTATATATTAATCAAGTACATAACATAAAAAATATATATATTAA  
GTGCAAATAGATTGAAAACAAATCAAGAAATTAATTAAGACACAGTGATTAAGCTTAAAACC  
CCATTTTGACTTGTTCTTTCTCAATGAATCCCTCACAAGCAGCAAGCTTCTTCGATTTTGCT  
TTGACACCACCAATCAGTGTTTTCGAATCTTTCAGGTTTGTCTCGATTTCAAAGTAGATCGG  
AGTCAAGTGATAAAATTGACTAACATAATTATCCCGTTCTCTCGTAAGAGTTGGGATTTAG  
25 CAGTAGATCGGAAATCGGAATTTACGTTTTTGTTAAAAGATTGATGGTTTAGGTAATAAAAC  
ATAGTTCTGGATTCATTGCTTCTAGTTGATTCTCGAATTGTTTGATTTTCGCAATGCACATTT  
TTGGTTCAAAGGATCACATAATTGCTTTAAAATTTGACAAAACATACCATCAAATTTCTCA  
TATTTCTTCAAGTAACTCGAAGTTGTTGGAAATCTATATACTCTGGGCTATGTAGATAAAGT  
CTTAACATTTTGGTCAACATTGTTTGTCTCTAAAGTCTGTTTAAAGTT

TGGTGCTTTCACTATTACACAGGTCTTATACAAGACTACAGTCTCTAGAAGCATAATATCGT  
CGACTCTGTTTTGAGTTTCCCAACAGTGGTTGAAGCTTAAGGAGGTTCTTATGTGCCTTTTG  
AAATC

5

SEQ ID NO: 7

CAAGCTTCTTCAATTTTGCTTGCTCTCTCTTACACGGCCAATCGGTGTTTTTCGCAGCTTT  
CAGGCCTCAATACAAGACATTCTATATAAGCATATTGCAGAAGAGGCGGTTCTAATTGTTGC  
10 ATGGAGTTGAACAATATGACGTAGGGAAATTCTAATTTAGGGGAGGCCTCAGAGTTTGCCT  
AACTTCATAATCAGCTCTGGACGTTGTTGATTGTATTTGAACAAGAATGTGTAGGCAGAATT  
GTCGCGCGAAATCCTCACCGGAGGAAGTGATTTCAACTGATGAGAATCTCTTGATATATTGT  
AAACCTGTTGCTATATAACATCTTTACCTTCGCTCTCTAGGCAACCCATCGTTTCTGCC  
AAGATGCTTGAAGTACAAAATTGGGGCAAAGCGCAAAGAAAGTCAAGATCTACTGGGATGG  
15 TAGTTTTCAACTATAAGGATTGTAATAATACATTACAAAGAACTGAAGTTAGGGAGGATTGT  
TCTTGCTCCATTTTGCTCTATGCTATGTGGTAGCTTCAAGGTGGGCAACTATTACAACTGAGG  
GGCTGCAATTTCAATTTGAATTCATCTCATGATTTATTTGAATTTGAGTTCAAGCTTTTGAA  
GAATACCAGACAGTTAATGTTTCTGTAAACTTAATTCCTTCATATTTGAGGAAGAAGGAAG  
TGATGATGATAAATTTGAGCCCTTCTCTCTCTGCTCGAAACCTCGTAAGCGTAGACAAAGAG  
20 GTGGCAGAAATAACACCAGGAGACTTAAAGTATGCTTTTTACCGTTGGATTCACCCAGTTTA  
GCTAATGGCACAGAAAATGGAATTGCCCTGCTGAATGATGGAAACCGTGGTTTAGGATATCC  
CGAGGCAACAGAGCTTGCTGGACAATTTGAGATGACTAGCAACATTCCACCAGCCATAGCCC  
ACTCTTCTCTGGACGCTGGTGCTAAAGTTATATTAACAACCGAAGCTGTGGTCCCTGCTACT  
AAGACAAGAAAGTTATCTGCTGAGCGATCAGAGGCTAGAAGCCACCTACTTCTTCAGAAACG  
25 CCAATTCTATCATTCTCACAGAGTCCAGCCAATGGCGCTTGAGCAAGTAATGTCTGATCGGG  
ATAGCGAGGATGAAGTCGATGACGATGTTGCAGATTTTGAAGATCGCCAGATGCTTGATGAC  
TTTGTGGATGTGAATAAAGATGAAAAGCAATTCATGCATCTTTGGAACTCGTTTGTAAGAAA  
ACAAAGGGTTATAGCAGATGGTCATATCTCTTGGGCATGTGAAGTATTTTCAAGATTTTACG  
AGAAAGAGTTGCACTGTTACTCATCACTCTTCTGGTGTTGGAGATTGTTTTTGATTAAACTA



TGGAACCATGGACTTGTCTGACTCAGCCACCATCAACAACTGCAATACCATCCTCGAGAATTG  
CCGTAATACCTCAGTCACTAACAACAACAACAGTGTGGATCATCCCAGTGACTCAAACA  
CCAACAACAATAACATTGTGGATCATCCGAATGACATAAAAAACAAGAACAATGTTGACAAC  
AAGGACAATAACAGCAGAGACAAGTAATTAAATAGGAAACACTCCGGTTTAGATGATACCGA  
5 TCTATCGGATTGTAACCTATTCTTCTTTCTTAAAAAAATTGTTTAGGAGCAAACAAAGATTT  
TATTTGTTAGTGTATTCAACTGATTACATTTTGTAGTTAAAAAAATGGATTCTCCTTAATAAC  
T

10 SEQ ID NO: 8

MCRQNCRAKSSPEEVISTDENLLIYCKPVRLYNIFHLRSLGNPSFLPRCLNYKIGAKRKRKS  
RSTGMVVFNYKDCNNTLQRTEVREDCSCPFCSMLCGSFKVGNYYN

15

SEQ ID NO: 9

ACATTTTCGTACCGCTCAAGATTTAAGAAGCGTAAAAGGGTGGAAATCTCAAGTGATAAAAT  
TAGGCATGTACATCCACATATTGTGGATTCAGGATCACCTGAAGATGCCCAGGCAGGATCTG  
20 AAGACGATTACGTGCAGAGGGGAAAATGGTAGTTCTGTAGCACACGCTTCTGTTGATCCTGCT  
AATTCATTACACGGTAGCAATCTTTCAGCACCAACAGTGTTACAGTTTGGGAAGACAAGAAA  
GCTGTCTGTTGAACGAGCTGATCCCAGAAATCGGCAGCTCCTACAAAACGCCAGTTCTTTC  
ATTCTCACAGGGCTCAACCAATGGCATTGGGAGCAGTTTTCTCAGATCGTGATAGTGAAGAT  
GAGGTTGATGATGACATTGCTGATTTTGAAGATAGACAGATGCTTGATGATTTTGTGATGT  
25 TACCAAAGACGAACTTATTATGCATATGG

SEQ ID NO: 10

TFSYRSRFFKKRKRVEISSDKIRHVHPHIVDSGSPEDAQAGSEDDYVQRENGSSVAHASVDPA  
NSLHGSNLSAPTVLQFGKTRKLSVERADPRNRQLLQKRQFFHSHRAQPMALGAVFSDRDESED  
EVDDDIADFEDRQMLDDFVDVTKDELIMHM

5

SEQ ID NO: 11

ACATGCATATCCTGATGCTGAATGTGCTCAATTGGTACCTGGGAATAATCTTGACACCTCCTG  
CCATGCTACAATTTGCAAAGACAAGAAAATTATCAATTGAACGGTCTGACATGAGAAACCGT  
10 ACACTCCTTCACAAACGACAATTTTTTCACTCACATAGAGCTCAGCCAATGGCAGCTGAGCA  
AGTTATGTCAGATCGGGATAGTGAGGATGAAGTTGACGATGATGTTGCAGATTTTGAAGACC  
GAAGGATGCTTGATGATTTTGTAGACGTGACTAAAGATGAGAAGCAAATGATGCACTTGTGG  
AACTCATTGTGAGG

15

SEQ ID NO: 12

HAYPDAECAQLVPGNNLAPPAMLQFAKTRKLSIERSDMRNRTLHHRQFFHSHRAQPMAAEQ  
VMSDRDSEDEVDDDVADFEDRRMLDDFVDVTKDEKQMMHLWNSFVR

20

SEQ ID NO: 13

ATGGATCCGATTAAGCTGACAACAGAAGCTAAGGTCCCTGCTAAGCGATCAAAGGCTACAAG  
25 CCACTACTTGCTCTTCATAAACGCCAGTTCTATCATTCCCGAACCGGTGAGCCATTGTCAC  
TTGAGCAAGTTATGTCTGACCGAGATAGCGAAAATGACGTGACAAAAATGATGATGCTGCA  
CATCTCGAAGAAAGCCAGATGCTTAATGGTTCCATGGATGAGAATGAAATCGTAGCAGAGAG  
ATTCATAAACTTTGGAACCTTTGTAAACAGCAAAGGATTGTTGCAGATGCTCATATTC  
CTTGGGCATGTGAAGCATTCTCAAGATTACACCTGCAAGAGCTGCGCAGTAACTTATCACTC

GACTTGTGCTGGAGACAATTCATGATCAAACAATGGGATTATGGACTTCTTGACAGAGTCAC  
CATGAACAAATGCAATACCATCATCTACCATAATATCTCAACTACCAACGATGACATAAACA  
ATAACAACACAAGGACGACTGATAATATGGATGTTGTGCGACGATGACATAAACAGAGACAAG

5

SEQ ID NO: 14

MDPIKLTTEAKVPAKRSKATSHYLPLHKRQFYHSRTGQPLSLEQVMSDRDSENDVDKNDDAA  
HLEESQMLNGSMDENEIVAERFIKLWNSFVKQQRIVADAHIPWACEAFSRLHLQELRSNLSL  
10 DLCWRQFMIKQWDYGLLDRVTMNCNTIIYHNI STTND DINNNNTRTTDNMDVVD DD INRDK

SEQ ID NO: 15

15 CTCTGAGGAGACACTTTTTTTTTTCCTCCCTCCTTCCCTCCTCTCCTCCTCCCTTCCCTTCCC  
CTCTCCTCCCCTCTCTCCTCCTTCCCCCCTCGGTCCGCCGAGCCTGCTGGGGCGAGCGGTT  
GGTATTGCAGGCGCTTGCTCTCCGGGGCCGCCCGGCGGGTAGCTGGCGGGGGGAGGAGGCAG  
GAACCGCGATGGCGCCTCAGAAGCACGGCGGTGGGGGAGGGGGCGGCTCGGGGCCCAGCGCG  
GGGTCCGGGGGAGGCGGCTTCGGGGGTTCGGCGGCGGTGGCGGCGGCGACGGCTTCGGGCGG  
20 CAAATCCGGCGGCGGGAGCTGTGGAGGGGTGGCAGTTACTCGGCCTCCTCCTCCTCCTCCG  
CGGCGGCAGCGGCGGGGGCTGCGGTGTTACCGGTGAAGAAGCCGAAAATGGAGCACGTCCAG  
GCTGACCACGAGCTTTTCCTCCAGGCCTTTGAGAAGCCAACACAGATCTATAGATTTCTTCG  
AACTCGGAATCTCATAGCACCAATATTTTTGCACAGAACTCTTACTTACATGTCTCATCGAA  
ACTCCAGAACAAACATCAAAAGGAAAACATTTAAAGTTGATGATATGTTATCAAAAGTAGAG  
25 AAAATGAAAGGAGAGCAAGAATCTCATAGCTTGTCAGCTCATTTGCAGCTTACGTTTACTGG  
TTTCTTCCACAAAAATGATAAGCCATCACCAAACCTCAGAAAATGAACAAAATTCTGTTACCC  
TGGAAGTCCTGCTTGTGAAAGTTTGCCACAAAAAAGAAAGGATGTAAGTTGTCCAATAAGG  
CAAGTTCCACAGGTAAAAAGCAGGTGCCTTTGATTCCTGACCTCAATCAAACAAAACCCGG  
AAATTTCCCGTCCCTTGCAAGTTTCCAGTAATGAATTTGAACCTAGTAACAGCCATATGGTGA

AGTCTTACTCGTTGCTATTTAGAGTGAAGTCCAGGAAGAAGAGAGTTTAATGGAATGATT  
AATGGAGAAACCAATGAAAATATTGATGTCAATGAAGAGCTTCCAGCCAGAAGAAAACGAAA  
TCGTGAGGATGGGGAAAAGACATTTGTTGCACAAATGACAGTATTTGATAAAAAACAGGCGCT  
TACAGCTTTTAGATGGGGAATATGAAGTAGCCATGCAGGAAATGGAAGAATGTCCAATAAGC  
5 AAGAAAAGAGCAACATGGGAGACTATTCTTGATGGGAAGAGGCTGCCTCCATTCGAAACATT  
TTCTCAGGGACCTACGTTGCAGTTCCTCTCGTTGGACAGGAGAGACCAATGATAAATCTA  
CGGCTCCTATTGCCAAACCTCTTGCCACTAGAAATTCAGAGAGTCTCCATCAGGAAAACAAG  
CCTGGTTCAGTTAAACCTACTCAAATATTGCTGTTAAAGAATCATTGACTACAGATCTACA  
AACAAGAAAAGAAAAGGATACTCCAAATGAAAACCGACAAAAATTAAGAATATTTTATCAGT  
10 TTCTCTATAACAACAATACAAGGCAACAACTGAAGCAAGAGATGACCTGCATTGCCCTTGG  
TGTACTCTGAACTGCCGCAAACTTTATAGTTTACTCAAGCATCTTAACTCTGCCATAGCAG  
ATTTATCTTCAACTATGTTTATCATCCAAAAGGTGCTAGGATAGATGTTTCTATCAATGAGT  
GTTATGATGGCTCCTATGCAGGAAATCCTCAGGATATTCATCGCCAACCTGGATTTGCTTTT  
AGTCGCAACGGACCAGTTAAGAGAACACCTATCACACATATTCTTGTGTGCAGGCCAAAACG  
15 AACAAAAGCAAGCATGTCTGAATTTCTTGAATCTGAAGATGGGGAAGTAGAACAGCAAAGAA  
CATATAGTAGTGGCCACAATCGTCTGTATTTCCATAGTGATACCTGCTTACCTCTCCGTCCA  
CAAGAAATGGAAGTAGATAGTGAAGATGAAAAGGATCCTGAATGGCTAAGAGAAAAAACCAT  
TACACAAATTGAAGAGTTTTCTGATGTTAATGAAGGAGAGAAAGAAGTGATGAAACTCTGGA  
ATCTCCATGTCATGAAGCATGGGTTTATTGCTGACAATCAAATGAATCATGCCTGTATGCTG  
20 TTTGTAGAAAATTATGGACAGAAAATAATTAAGAAGAATTTATGTCGAACTTCATGCTTCA  
TCTAGTCAGCATGCATGACTTTAATCTTATTAGCATAATGTCAATAGATAAAGCTGTTACCA  
AGCTCCGTGAAATGCAGCAAAAATTAGAAAAGGGGGAATCTGCTTCCCCTGCAAACGAAGAA  
ATAACTGAAGAACAAAATGGGACAGCAAATGGATTTAGTGAAATTAATCAAAAAGAGAAAGC  
TTTGGAACAGATAGTGTCTCAGGGGTTTCAAAAACAGAGCAAAAAACAAAACTCTGAAAAG  
25 CTCTAACCCCATGTTATGGACAAACACTGAAATTACATTTTAGGGAATTCATCCTCTAAGAA  
TTATGTTTTTGTTTTAAATCATATGTTCCAAACAGGCACTGTTAGATGAAGTAAATGATTTT  
AACAAGGATATTTGTATCAGGGTCTACTTCACTTCATTATGCAGCATTACATGTATATCAC  
TTTTATTGATGTCATTAAACATTCTGTACTTTAAGCATGAAAAGCAATATTTCAAAGTATT  
TTTAACTCAACAAATGTCATCAAATATGTTGAATTGATCTAGAAATTATTTATATATAAA

TCAGAATTTTTTGCATTTATGAACGGCTGTTTTCTACTTTGTAATTGTGAGACATTTTCT  
TGGGGAGGGAAAATTGGAATGGTTCCTTTTTTAGAAATTGAAGTGGTCTTCATATGTCAAC  
TACAGAAAAGGAAAAAATAGAAATTGAAGGATTTTTATGAAATTATATTGCATTACTATTT  
GCAGTCAAACCTTTGATCCTTGTTTTTGAATCATTTGTCAATTCGGAATGAAAAATTATAAT  
5 GTAATTTTACATTACATAAGTTCCTTTTACAATTAAAAAATAGCACTTCTTCATCTTATGCC  
TGTTTGAGAAGATATTAAATTTTACATTGTTGACAGTGAAATGCTATGTTGGTTTATAAGA  
TTACAGACCATTTGTTTTCATGTGGATAATTTTAGTGCATTGCTCACCCGGTATGTTTTTTT  
TTTTTAACCTGAACATTTTGCTTGTTTTGTTTTTCTTTTTTAATTAGATAATCACACGGAAA  
ATTAAGCTGTTTCATATCTTTAAATTAGGATTGCAAACCAAGGAAAGAACGCATTTGAGATTT  
10 TAAGATGTCACTTATAAGGGGAGAAGTGTCTTAAAAAGTCAACCAGAAAACCTGTTATGCCT  
TTTATTTGTTTGCAAGGATGTCTTTGTAATGTGTTTCATGAATAGAATATCCAATAGAGATA  
AGCTGACTTGAATCATTTTGAGCAATTTTGCCCTGTGTTATATGTGTTTCACGCACATATTT  
GCAGTTGGATTTTCTCCAACAGAAAGTGGATTCACTACTGGCACATTAACAAGCACCAATAG  
GTTTTTATTCCAACCTCCGAGCACTGTGGTTGAGTAACATCACCTCAATTTTTTATTATCCTT  
15 AAAGATATTGCATTTTCATATTCTTTATTTATAAAGGATCAATGCTGCTGTAAATACAGGTA  
TTTTTAATTTTAAAATTTTCAATCCACCACCATCAGATGCAGTTCCTATTTTGTTTAATGAA  
GGGATATATAAGCTTTCTAATGGTGTCTTCAGAAATTTATAAAATGTAAATACTGATTTGAC  
TGGTCTTTAAGATGTGTTTAACTGTGAGGCTATTTAACGAATAGTGTGGATGTGATTTGTCA  
TCCAGTATTAAGTTCTTAGTCATTGATTTTTTGTGTTTAAAAAAAATAGGAAAGAGGGAAAC  
20 TGCAGCTTTCATTACAGATTCCTTGATTGGTAAGCTCTCCAAATGATGAGTTCTAGTAAACT  
CTGATTTTTGCCTCTGGATAGTAGATCTCGAGCGTTTATCTCGGGCTTTAATTTGCTAAAGC  
TGTGCACATATGTAAAAAAGATTATTTTAGGGGAGATGTAGGTGTAGAATT  
ATTGCTTATGTCATTTCTTAAGCAGTTATGCTCTTAATGCTTAAAAGAAGGCTAGCATTGTT  
TGCACAAAAGTTGGTGATTCCCACCCCAAATAGTAATAAAATTACTTCTGTTGAGTAAACT  
25 TTTTATGTCATCGTAAAAGCTGGAAAAATCCCTTTGTTTCTATTTATAAAAAAAGTGCTTTT  
CTATATGTACCCTTGATAACAGATTTTGAAGAAATCCTGTAAGATGATAAAGCATTGGAATG  
GTACAGTAGATGTAAAAAATTCAGTTTAAAAGAACATTTGTTTTTACATTAAATGTTTAT  
TTGAAATCAAATGATTTTGTACATAAAGTTCAATAATAT

SEQ ID NO: 16

LRRHFFPPSPFPLLLPSLPLSSPLSSFPPRSAGACWGERLVLQALALRGRPAGSWRGEEAG  
TAMAPQKHGGGGGGGSGPSAGSGGGGFGGSAAVAAATASGGKSGGGSCGGGGSYSASSSSSA  
5 AAAAGAAVLPVKKPKMEHVQADHELFLQAF EKPTQIYRFLRTRNLIAPIFLHRTLTYMSHRN  
SRTNKRKTFKVDDMLSKVEKMKGEQESHLSAHLQLTFTGFFHKNDKPSPNSENEQNSVTL  
EVLLVKVCHKKRKDVSCPIRQVPTGKKQVPLIPDLNQTKPGNFPSLAVSSNEFEPSNSHMK  
SYSLLFRVTRPGRREFNGMINGETNENIDVNEELPARRKRNREDGEKTFVAQMTVFDKNRRL  
QLLDGEYEVAMQEMECPISKKRATWETILDGKRLPPFETFSQGPTLQFTLRWTGETNDKST  
10 APIAKPLATRNSSESLHQENKPGSVKPTQTI AVKESLTDLQTRKEKDTPNENRQKLRIFYQF  
LYNNNTRQQTEARDDLHCPWCTLNCRKLYSLLKHLKLCHSRFIFNYVYHPKGARIDVSINEC  
YDGSYAGNPQDIHRQPGFAFSRNGPVKRTPI THILVCRPKRTKASMSEFLESEDGEVEQQRT  
YSSGHNRLYFHS DTCPLRPQEMEVDSEDEKDPEWLREKTITQIEEFSDVNEGEKEVMKLWN  
LHVMKHGFIADNQMNHACMLFVENYGQKIIKKNL CRNFMLHLVSMHDFNLISIMSIDKAVTK  
15 LREMQQKLEKGESASPANEEITEEQNGTANGFSEINSKEKALETDSVSGVSKQSKKQKL

Figure 1









Figure 2

2

A



B






Figure 3






Figure 4






Figure 5








Figure 6

TTCTTCAATTTTGCTTGTCTCTCTTACACAGCCAATCGGTGTTTTCGCAGCTTTTCAGGCCTCAATCCAAGACAT	5
TCTATATAAGCATATTGCAGAAGAGGCGGTCTAATGTGTGCATTGAGTTTATCGCTATGACGTAGGGAAATCT	80
AATTTAGGGAGGCCTCAGAGTTTGCACTAACTTCATAATCGGCTCTTGACGTTGTTGAGTGAATTGAACAAGA	155
ATGTGTAGGCAGAATTGTTCGCGGAAATCCTCACCAGGAGGAAGTGATTTCAACTGATGAGAATCTCTTGATATAT	230
M C R Q N C R A K S S P E E V I S T D E N L L I Y	305
TGTAACCTGTTTCGACTATATAACATCTTTACCTTCGCTCTCTAGGCAACCCATCGTTTCTTCCAAGATGCTTG	380
C K P V R L Y N I F H L R S L G N P S F L P R C L	50
AACTACAAAATTGGAGCAAAGCGCAAAAGAAAGTCAAGATCTACTGGGATGGTAGTTTTCAACTATAAGGATTGT	455
N Y K I G A <u>K R K R K</u> S R S T G M V V F N Y K D C	75
AATAACACATTACAGAAAAGTGAAGTTAGGGAGGATTGTTCTTGTCCATTTTGCTCTATGCTATGTGGTAGCTTC	530
N N T L Q K T E V R E D C S <u>C P F C S M L C G S F</u>	100
AAGGGCTGCAATTTCAATTGAATTCATCTCATGATTATTGGAATTTGAGTTCAAGCTTTTCGAAGAATACCAG	605
<u>K G L Q F H L N S S H</u> D L F E F E F K L F E E Y Q	125
ACAGTTAATGTTTCTGTAAACTTAATTCCTTCATATTGAGGAAGAAGGAAGTGATGACGATAAATTTGAGCCC	680
T V N V S V K L N S F I F E E E G S D D D K F E P	150
TTCTCTCTCTGCTCGAAACCTCGTAAGCGGAGACAAAGAGGTGGCAGAAATAACACCAGGAGACTTAAAGTATGC	755
F S L C S K P <u>R K</u> R R Q R G G R N N T <u>R R L K V</u> C	175
TTTTTACCGTTGGATTACCCAGTTTAACTAATGGCACAGAAAATGGAATCACCTACTTAATGATGGAAACCGT	830
F L P L D S P S L T N G T E N G I T L L N D G N R	200
GGTTTAGGATATCCCGAGGCAACAGAGCTTGTCTGGACAATTTGAGATGACCAGCAACATTCCACCAGCCATAGCC	905
G L G Y P E A T E L A G Q F E M T S N I P P A I A	225
CACTCTTCTCTGGACGCTGGTGTAAAGTTATATTGACAAGCGAAGCTGTGGTCCTTGCTACTAAGACAAGAAAG	980
H S S L D A G A K V I L T S E A V V P A T K T R K	250
TTATCTGCTGAGCGATCAGAGGCTAGAAGCCACCTACTTCTTCAGAAACGCCAATTCTATCATTCTCACAGATC	1055
L S A E R S E A R S H L L L Q K R Q F Y H S H R V	275
CAGCCAATGGGCTTGAGCAAGTAATGTCTGACCGGGATAGCGAGGATGAAGTCGATGACGATGTTGCAGATTTT	1130
Q P M A L <u>E Q V M S D R D S E D E V D D D V A D E</u>	300
GAAGATCGCCAGATGCTTGTGATGACTTTGTGGATGTGAATAAAGATGAAAAGCAATTTCATGCATCTTTGGAACCTG	1205
<u>E D R Q M L D D F V D V N K D E K Q F M H L</u> (W) N S	325
TTTGTAAGAAAACAAAGGTTATAGCAGATGGTCATATCTCTTGGGCATGTGAAGCATTTCAGATTTCACGAG	1280
F V R K Q R V I A D G H I S W A C E A F S R F Y E	350
AAAGAGTTGCACCGTTACTCATCTCTTCTGGTGTGGAGATTGTTTTGATTAACTATGGAACCATGGACTT	1355
K E L H R Y S S L F W C W R L F L I K L W N H G L	375
GTCGACTCAGCCACCATCAACAAGTGAATACCATCCTCGAGAATTGCCGTAATAGCTCAGACACCACCACCACC	1430
V D S A T I N N C N T I L E N C R N S S D T T T T	400
AACAACAACAACAGTGTGGATCGTCCAGTGACTCAAACACCAACAACAATAACATTGTGGATCATCCCAATGAC	1505
N N N N S V D R P S D S N T N N N N I V D H P N D	425
ATAAACAACAAGAACAATGTTGACAACAAGGACAATAACAGCAGAGACAAAGTAATTAAATAGGAAAAATCTCCGG	1580
I N N K N N V D N K D N N S R D K V I K	445
CTTTTATGATACCGATTATCGGATTGTAACCTATTCTTCTTTCTTAAAAAATTGTTTAGGAGCAAAACAATTTT	1655
TTATATGTTAGTGATTCAACTGATTACATTTTATAGTTAAAAAATAATGGAATCTGCTTATAACT	1722



Figure 7

*fca-1* W323  
*vrn2-1* GAAAAGCAATTCATGCATCTT TGG AACTCGTTTGTAAGAA  
 TGA  
 STOP

GAAAAGCAATTCATGCATCTTTGAAACTCGTTTGTAAGAA  
 CTTNNNNNAAG  
 Xmn I site

Diagnostic Primer: VRN2-AZ Antisense 3' TGAGAAAGACATTCCTTTGTTCCATTGATGAAGAG 5'  
 (contains a A and G mismatches at positions 5,7) (CTT)NNNNNAAG  
 Xmn I half-site

Upstream Primer: VRN2-AY 5' TGCCTTCATTAAAGTAGGCAACAGAAAATGG 3'

Product:

170 bp PCR product for both *fca-1* and *vrn2-1*

PCR Products:

*fca-1* GAAAAGCAATTCATGCATCTTTGGAACCTCTTCTGTAAGAA  
*vrn2-1* GAAAAGCAATTCATGGATCTTTGAAACTCTTCTGTAAGAA

Xmn I digest => *fca-1* no Xmn I site 170 bp  
*vrn2-1* single Xmn I site 137 bp, 33 bp fragments



Figure 8a

VRN2 Ler	M	C	R	Q	N	C	R	A	K	S	S	P	E	E	V	I	S	T	D	E	20
AI163743 Prot	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1
Rice C72616	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1
At Hyp 2245035	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1
KIA00160	I	-	-	-	-	A	K	P	L	A	T	R	N	S	E	S	L	H	Q	E	452
VRN2 Ler	N	L	L	I	Y	C	K	P	V	R	L	Y	N	I	F	H	L	R	S	L	40
AI163743 Prot	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	
Rice C72616	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	
At Hyp 2245035	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	
KIA00160	N	K	P	G	S	V	K	P	T	Q	-	-	-	-	-	-	-	-	T	I	464
VRN2 Ler	G	N	P	S	F	L	P	R	C	L	N	Y	K	I	G	A	K	R	K	R	60
AI163743 Prot	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	
Rice C72616	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	
At Hyp 2245035	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	
KIA00160	A	V	K	E	S	L	T	T	D	L	Q	T	R	K	E	K	D	T	P	N	484
VRN2 Ler	K	S	R	S	T	G	M	V	V	F	N	Y	K	D	C	N	N	T	L	Q	80
AI163743 Prot	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	
Rice C72616	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	
At Hyp 2245035	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	
KIA00160	E	N	R	Q	K	L	R	I	F	Y	Q	F	L	Y	N	N	N	T	R	Q	504
VRN2 Ler	K	T	E	V	R	E	D	C	S	C	P	F	C	S	M	L	C	G	S	F	100
AI163743 Prot	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	
Rice C72616	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	
At Hyp 2245035	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	
KIA00160	Q	T	E	A	R	D	D	L	H	C	P	W	C	T	L	N	C	R	K	L	524
VRN2 Ler	K	G	L	Q	F	H	L	N	S	S	H	D	L	F	E	F	E	F	K	L	120
AI163743 Prot	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	
Rice C72616	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	
At Hyp 2245035	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	
KIA00160	Y	S	L	L	K	H	L	K	L	C	H	S	R	F	I	F	N	Y	V	Y	544



-----

Figure 8a

VRN2 Ler	F	E	E	Y	Q	T	V	N	V	S	V	K	L	N	S	F	I	F	E	E	140	
Al163743 Prot	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	
Rice C72616	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	
At Hyp 2245035	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	
KIA00160	H	P	K	G	A	R	I	D	V	S	I	N	-	-	-	-	-	-	-	-	557	
VRN2 Ler	E	G	S	D	D	K	F	E	P	F	S	L	C	S	K	P	R	K	R	160		
Al163743 Prot	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1		
Rice C72616	-	-	-	-	-	-	-	-	-	T	F	S	Y	R	S	R	F	K	K	10		
At Hyp 2245035	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1		
KIA00160	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	557		
VRN2 Ler	R	Q	R	G	G	R	N	N	T	R	R	L	K	V	C	F	L	P	L	D	180	
Al163743 Prot	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1		
Rice C72616	R	K	R	V	E	I	S	S	D	K	I	R	H	V	H	P	H	I	V	D	30	
At Hyp 2245035	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1		
KIA00160	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	557		
VRN2 Ler	S	P	S	L	T	N	G	T	E	N	G	I	T	L	L	N	D	G	N	R	200	
Al163743 Prot	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1		
Rice C72616	S	G	S	P	E	D	A	Q	A	G	S	E	D	D	Y	V	Q	R	E	N	50	
At Hyp 2245035	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1		
KIA00160	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	E	C	Y	D	560	
VRN2 Ler	G	L	G	Y	P	E	A	T	E	L	A	G	Q	Q	F	E	M	T	S	N	I	220
Al163743 Prot	-	H	A	Y	P	D	A	E	-	-	C	A	Q	Q	L	V	P	G	N	L	17	
Rice C72616	G	S	S	V	A	H	A	S	V	D	P	A	N	S	L	H	G	S	N	L	70	
At Hyp 2245035	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1		
KIA00160	G	S	Y	A	G	N	P	Q	D	I	H	R	Q	Q	P	G	F	A	F	S	580	
VRN2 Ler	P	P	A	I	A	H	S	S	L	D	A	G	A	K	V	I	L	T	S	E	240	
Al163743 Prot	A	P	P	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	21		
Rice C72616	S	A	P	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	74		
At Hyp 2245035	-	-	-	-	-	-	-	-	-	-	M	D	P	I	K	L	T	T	E	9		
KIA00160	N	G	P	V	K	R	T	P	I	T	H	I	L	V	C	R	P	K	R	I	600	





Figure 8a

VRN2 Ler	A V V P A T K T R K L S A E E R S S E D A R S	260
Al163743 Prot	A M L Q F F A K K T R K L S I V E E R S S D M R N	40
Rice C72616	T V L Q F F A K K T R K L S I V E E R S S D M R N	93
At Hyp 2245035	A K V P A - - - - - K E E R S S K A T S	21
KIA00160	K A S M S E F L E S E D G E E R S S K A T S	620
VRN2 Ler	H L L L Q K R Q F F Y H S H R R V Q P M A	279
Al163743 Prot	R T L L L Q K R Q F F Y H S H R R V Q P M A	59
Rice C72616	R Q L L L Q K R Q F F Y H S H R R V Q P M A	112
At Hyp 2245035	H Y S L P L H Q K R Q F F Y H S H R R V Q P M A	41
KIA00160	Y S L P L H Q K R Q F F Y H S H R R V Q P M A	639
VRN2 Ler	L E Q V M S D R R D S E E D E E V D - D D V	297
Al163743 Prot	A E Q V M S D R R D S E E D E E V D - D D V	77
Rice C72616	L G A V M S D R R D S E E D E E V D - D D V	130
At Hyp 2245035	L E Q V M S D R R D S E E D E E V D - D D V	61
KIA00160	P Q E M - E V D S E E D E E V D - D D V	655
VRN2 Ler	A D F E D R R Q M L D D F V D V N K D - E	316
Al163743 Prot	A D F E D R R Q M L D D F V D V N K D - E	96
Rice C72616	A D F E D R R Q M L D D F V D V N K D - E	149
At Hyp 2245035	A H L E E S Q M L N G S M D E N E I V A	81
KIA00160	L R E K T I Q I E E F S D V N E G - E	674
VRN2 Ler	K Q F M H L W N S F V R K Q R V I A D G	336
Al163743 Prot	K Q F M H L W N S F V R K Q R V I A D G	108
Rice C72616	- L I M H M	154
At Hyp 2245035	E R F I K L W N S F V K Q Q R I V A D A	101
KIA00160	K E V M K L W N L H V M K H G F I A D N	694
VRN2 Ler	H I S W A C E A F S R F Y E K E L H R Y	356
Al163743 Prot	H I S W A C E A F S R F Y E K E L H R Y	108
Rice C72616	H I P W A C E A F S R L H L Q E L R S N	154
At Hyp 2245035	H I P W A C E A F S R L H L Q E L R S N	121
KIA00160	Q M N H A C M L F V E N Y G Q K I K	714




Figure 8a

VRN2 Ler	S	S	L	F	W	C	W	R	L	F	L	I	K	L	W	N	H	G	L	V	376
AI163743 Prot																				108	
Rice C72616	L	S	L	D	L	C	W	R	Q	F	M	I	K	Q	W	D	Y	G	L	L	154
At Hyp 2245035	-	N	L	C	R	N	F	M	L	H	L	V	S	M	H	D	F	N	L	I	141
KIA00160																				733	
VRN2 Ler	D	S	A	T	I	N	N	C	N	T	I	L	E	N	C	R	N	S	S	D	396
AI163743 Prot																				108	
Rice C72616	D	R	V	T	M	N	K	C	N	T	I	L	Y	H	N	I	S	T	T	N	154
At Hyp 2245035	S	I	M	S	I	D	K	A	V	T	K	L	R	E	M	Q	Q	K	L	E	161
KIA00160																				753	
VRN2 Ler	T	T	T	T	N	N	N	N	S	V	D	R	P	S	D	S	N	T	N	N	416
AI163743 Prot																				108	
Rice C72616	D	D	I	N	N	N	N	T	R	T	T	D	N	M	D	V	V	D	D	D	154
At Hyp 2245035	K	G	E	S	A	S	P	A	N	E	E	I	T	E	E	Q	N	G	T	A	181
KIA00160																				773	
VRN2 Ler	N	N	I	V	D	H	P	N	D	I	N	N	K	N	N	V	D	N	K	D	436
AI163743 Prot																				108	
Rice C72616	I	N	R	D	K															154	
At Hyp 2245035	N	G	F	S	E	I	N	S	K	E	K	A	L	E	T	D	S	V	S	G	186
KIA00160																				793	
VRN2 Ler	N	N	S	R	D	K	V	I	K											445	
AI163743 Prot																				108	
Rice C72616																				154	
At Hyp 2245035																				186	
KIA00160	V	S	K	Q	S	K	K	Q	K	L										803	



Figure 8b

VRN2 Ler  
 At Di19 S51478  
 At Di19 S51478  
 At SUP U38946  
 At Hyp 2191171  
 At Hyp 3377806  
 Sc Pep7 91500  
 Sc TFIIA 730931  
 Sp Hyp 1351713  
 Ce Hyp 255942  
 Ce Hyp 2854197  
 Ce Hyp 304459  
 Dm BRCORE-NS-Z3  
 Dm GAGA 729556  
 Dm ken 3550814  
 Hs ATBF-1 976347  
 Hs KIA00160  
 Hs ZNF142 3123312  
 Mm FOG 2252814  
 Mm Spalt 1296845  
 Rn Roaz 2149792  
 Xm ZF1 532083



PCT 48.00 / 00028

28-1-00

newburn Ellis